
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Conventional heart failure therapy in cardiac ATTR amyloidosis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="8E59B56B925FC4533AB56B0051366D71.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="ehj">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10424879/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="European Heart Journal">
<meta name="citation_title" content="Conventional heart failure therapy in cardiac ATTR amyloidosis">
<meta name="citation_author" content="Adam Ioannou">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Paolo Massa">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Rishi K Patel">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Yousuf Razvi">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Aldostefano Porcari">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author_institution" content="Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Via Giacomo Puccini, Trieste 34100, Italy">
<meta name="citation_author" content="Muhammad U Rauf">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Anita Jiang">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Giacomo Cabras">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Stefano Filisetti">
<meta name="citation_author_institution" content="Cardiology University Department, IRCCS Policlinico San Donato, Piazza Edmondo Malan, Milan 20097, Italy">
<meta name="citation_author" content="Roos E Bolhuis">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Francesco Bandera">
<meta name="citation_author_institution" content="Cardiology University Department, IRCCS Policlinico San Donato, Piazza Edmondo Malan, Milan 20097, Italy">
<meta name="citation_author" content="Lucia Venneri">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Ana Martinez-Naharro">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Steven Law">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Tushar Kotecha">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Ruta Virsinskaite">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Daniel S Knight">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Michele Emdin">
<meta name="citation_author_institution" content="Health Science Interdisciplinary Center, Scuola Superiore Sant’Anna, Via Giuseppe Moruzzi, Pisa 56127, Italy">
<meta name="citation_author_institution" content="Cardiovascular Department, Fondazione Toscana Gabriele Monasterio, Via Giuseppe Moruzzi, Pisa 56124, Italy">
<meta name="citation_author" content="Aviva Petrie">
<meta name="citation_author_institution" content="Biostatistics Unit, University College London Eastman Dental Institute, 256 Grays Inn Road, London WC1X 8LD, UK">
<meta name="citation_author" content="Helen Lachmann">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Ashutosh Wechelakar">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Mark Petrie">
<meta name="citation_author_institution" content="BHF Cardiovascular Research Centre, University of Glasgow, 126 University Pl, Glasgow G12 8TA, UK">
<meta name="citation_author" content="Alun Hughes">
<meta name="citation_author_institution" content="Institute of Cardiovascular Science, University College London, 1–19 Torrington Place, London WC1E 7HB, UK">
<meta name="citation_author" content="Nick Freemantle">
<meta name="citation_author_institution" content="University College London, London, UK">
<meta name="citation_author" content="Philip N Hawkins">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Carol Whelan">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="John J V McMurray">
<meta name="citation_author_institution" content="BHF Cardiovascular Research Centre, University of Glasgow, 126 University Pl, Glasgow G12 8TA, UK">
<meta name="citation_author" content="Julian D Gillmore">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_author" content="Marianna Fontana">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK">
<meta name="citation_publication_date" content="2023 May 22">
<meta name="citation_volume" content="44">
<meta name="citation_issue" content="31">
<meta name="citation_firstpage" content="2893">
<meta name="citation_doi" content="10.1093/eurheartj/ehad347">
<meta name="citation_pmid" content="37216684">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC10424879/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC10424879/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC10424879/pdf/ehad347.pdf">
<meta name="description" content="The aims of this study were to assess prescription patterns, dosages, discontinuation rates, and association with prognosis of conventional heart failure medications in patients with transthyretin cardiac amyloidosis (ATTR-CA). A retrospective ...">
<meta name="og:title" content="Conventional heart failure therapy in cardiac ATTR amyloidosis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="The aims of this study were to assess prescription patterns, dosages, discontinuation rates, and association with prognosis of conventional heart failure medications in patients with transthyretin cardiac amyloidosis (ATTR-CA). A retrospective ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC10424879/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="10424879">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1093/eurheartj/ehad347"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/ehad347.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC10424879%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/10424879/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/10424879/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC10424879/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-ehj.png" alt="European Heart Journal logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to European Heart Journal" title="Link to European Heart Journal" shape="default" href="http://eurheartj.oxfordjournals.org/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Eur Heart J</button></div>. 2023 May 22;44(31):2893–2907. doi: <a href="https://doi.org/10.1093/eurheartj/ehad347" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1093/eurheartj/ehad347</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22Eur%20Heart%20J%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Eur%20Heart%20J%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Eur%20Heart%20J%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Eur%20Heart%20J%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Conventional heart failure therapy in cardiac ATTR amyloidosis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ioannou%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Adam Ioannou</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Adam Ioannou</span></h3>
<div class="p">
<sup>1</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ioannou%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Adam Ioannou</span></a>
</div>
</div>
<sup>1,</sup><sup>b</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Massa%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Paolo Massa</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Paolo Massa</span></h3>
<div class="p">
<sup>2</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Massa%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Paolo Massa</span></a>
</div>
</div>
<sup>2,</sup><sup>b</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Patel%20RK%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Rishi K Patel</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Rishi K Patel</span></h3>
<div class="p">
<sup>3</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Patel%20RK%22%5BAuthor%5D" class="usa-link"><span class="name western">Rishi K Patel</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Razvi%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Yousuf Razvi</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Yousuf Razvi</span></h3>
<div class="p">
<sup>4</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Razvi%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yousuf Razvi</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Porcari%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Aldostefano Porcari</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Aldostefano Porcari</span></h3>
<div class="p">
<sup>5</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">
<sup>6</sup>
Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Via Giacomo Puccini, Trieste 34100, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Porcari%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Aldostefano Porcari</span></a>
</div>
</div>
<sup>5,</sup><sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rauf%20MU%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Muhammad U Rauf</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Muhammad U Rauf</span></h3>
<div class="p">
<sup>7</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rauf%20MU%22%5BAuthor%5D" class="usa-link"><span class="name western">Muhammad U Rauf</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jiang%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Anita Jiang</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Anita Jiang</span></h3>
<div class="p">
<sup>8</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jiang%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Anita Jiang</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cabras%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Giacomo Cabras</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Giacomo Cabras</span></h3>
<div class="p">
<sup>9</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cabras%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Giacomo Cabras</span></a>
</div>
</div>
<sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Filisetti%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Stefano Filisetti</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Stefano Filisetti</span></h3>
<div class="p">
<sup>10</sup>
Cardiology University Department, IRCCS Policlinico San Donato, Piazza Edmondo Malan, Milan 20097, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Filisetti%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Stefano Filisetti</span></a>
</div>
</div>
<sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bolhuis%20RE%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Roos E Bolhuis</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Roos E Bolhuis</span></h3>
<div class="p">
<sup>11</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bolhuis%20RE%22%5BAuthor%5D" class="usa-link"><span class="name western">Roos E Bolhuis</span></a>
</div>
</div>
<sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bandera%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Francesco Bandera</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Francesco Bandera</span></h3>
<div class="p">
<sup>12</sup>
Cardiology University Department, IRCCS Policlinico San Donato, Piazza Edmondo Malan, Milan 20097, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bandera%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Francesco Bandera</span></a>
</div>
</div>
<sup>12</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Venneri%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Lucia Venneri</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Lucia Venneri</span></h3>
<div class="p">
<sup>13</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Venneri%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lucia Venneri</span></a>
</div>
</div>
<sup>13</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Martinez-Naharro%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Ana Martinez-Naharro</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Ana Martinez-Naharro</span></h3>
<div class="p">
<sup>14</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Martinez-Naharro%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Ana Martinez-Naharro</span></a>
</div>
</div>
<sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Law%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Steven Law</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Steven Law</span></h3>
<div class="p">
<sup>15</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Law%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Steven Law</span></a>
</div>
</div>
<sup>15</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kotecha%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Tushar Kotecha</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Tushar Kotecha</span></h3>
<div class="p">
<sup>16</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kotecha%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Tushar Kotecha</span></a>
</div>
</div>
<sup>16</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Virsinskaite%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Ruta Virsinskaite</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Ruta Virsinskaite</span></h3>
<div class="p">
<sup>17</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Virsinskaite%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Ruta Virsinskaite</span></a>
</div>
</div>
<sup>17</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Knight%20DS%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Daniel S Knight</span></a><div hidden="hidden" id="id17">
<h3><span class="name western">Daniel S Knight</span></h3>
<div class="p">
<sup>18</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Knight%20DS%22%5BAuthor%5D" class="usa-link"><span class="name western">Daniel S Knight</span></a>
</div>
</div>
<sup>18</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Emdin%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western">Michele Emdin</span></a><div hidden="hidden" id="id18">
<h3><span class="name western">Michele Emdin</span></h3>
<div class="p">
<sup>19</sup>
Health Science Interdisciplinary Center, Scuola Superiore Sant’Anna, Via Giuseppe Moruzzi, Pisa 56127, Italy</div>
<div class="p">
<sup>20</sup>
Cardiovascular Department, Fondazione Toscana Gabriele Monasterio, Via Giuseppe Moruzzi, Pisa 56124, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Emdin%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Michele Emdin</span></a>
</div>
</div>
<sup>19,</sup><sup>20</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Petrie%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id19"><span class="name western">Aviva Petrie</span></a><div hidden="hidden" id="id19">
<h3><span class="name western">Aviva Petrie</span></h3>
<div class="p">
<sup>21</sup>
Biostatistics Unit, University College London Eastman Dental Institute, 256 Grays Inn Road, London WC1X 8LD, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Petrie%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Aviva Petrie</span></a>
</div>
</div>
<sup>21</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lachmann%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id20"><span class="name western">Helen Lachmann</span></a><div hidden="hidden" id="id20">
<h3><span class="name western">Helen Lachmann</span></h3>
<div class="p">
<sup>22</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lachmann%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Helen Lachmann</span></a>
</div>
</div>
<sup>22</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wechelakar%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id21"><span class="name western">Ashutosh Wechelakar</span></a><div hidden="hidden" id="id21">
<h3><span class="name western">Ashutosh Wechelakar</span></h3>
<div class="p">
<sup>23</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wechelakar%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Ashutosh Wechelakar</span></a>
</div>
</div>
<sup>23</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Petrie%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id22"><span class="name western">Mark Petrie</span></a><div hidden="hidden" id="id22">
<h3><span class="name western">Mark Petrie</span></h3>
<div class="p">
<sup>24</sup>
BHF Cardiovascular Research Centre, University of Glasgow, 126 University Pl, Glasgow G12 8TA, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Petrie%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mark Petrie</span></a>
</div>
</div>
<sup>24</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hughes%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id23"><span class="name western">Alun Hughes</span></a><div hidden="hidden" id="id23">
<h3><span class="name western">Alun Hughes</span></h3>
<div class="p">
<sup>25</sup>
Institute of Cardiovascular Science, University College London, 1–19 Torrington Place, London WC1E 7HB, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hughes%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alun Hughes</span></a>
</div>
</div>
<sup>25</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Freemantle%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id24"><span class="name western">Nick Freemantle</span></a><div hidden="hidden" id="id24">
<h3><span class="name western">Nick Freemantle</span></h3>
<div class="p">
<sup>26</sup>
University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Freemantle%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Nick Freemantle</span></a>
</div>
</div>
<sup>26</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hawkins%20PN%22%5BAuthor%5D" class="usa-link" aria-describedby="id25"><span class="name western">Philip N Hawkins</span></a><div hidden="hidden" id="id25">
<h3><span class="name western">Philip N Hawkins</span></h3>
<div class="p">
<sup>27</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hawkins%20PN%22%5BAuthor%5D" class="usa-link"><span class="name western">Philip N Hawkins</span></a>
</div>
</div>
<sup>27</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Whelan%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id26"><span class="name western">Carol Whelan</span></a><div hidden="hidden" id="id26">
<h3><span class="name western">Carol Whelan</span></h3>
<div class="p">
<sup>28</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Whelan%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Carol Whelan</span></a>
</div>
</div>
<sup>28</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22McMurray%20JJV%22%5BAuthor%5D" class="usa-link" aria-describedby="id27"><span class="name western">John J V McMurray</span></a><div hidden="hidden" id="id27">
<h3><span class="name western">John J V McMurray</span></h3>
<div class="p">
<sup>29</sup>
BHF Cardiovascular Research Centre, University of Glasgow, 126 University Pl, Glasgow G12 8TA, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22McMurray%20JJV%22%5BAuthor%5D" class="usa-link"><span class="name western">John J V McMurray</span></a>
</div>
</div>
<sup>29</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gillmore%20JD%22%5BAuthor%5D" class="usa-link" aria-describedby="id28"><span class="name western">Julian D Gillmore</span></a><div hidden="hidden" id="id28">
<h3><span class="name western">Julian D Gillmore</span></h3>
<div class="p">
<sup>30</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gillmore%20JD%22%5BAuthor%5D" class="usa-link"><span class="name western">Julian D Gillmore</span></a>
</div>
</div>
<sup>30,</sup><sup>c</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fontana%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id29"><span class="name western">Marianna Fontana</span></a><div hidden="hidden" id="id29">
<h3><span class="name western">Marianna Fontana</span></h3>
<div class="p">
<sup>31</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fontana%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Marianna Fontana</span></a>
</div>
</div>
<sup>31,</sup><sup>✉,</sup><sup>c</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>1</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff2">
<sup>2</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff3">
<sup>3</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff4">
<sup>4</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff5">
<sup>5</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff6">
<sup>6</sup>
Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Via Giacomo Puccini, Trieste 34100, Italy</div>
<div id="aff7">
<sup>7</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff8">
<sup>8</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff9">
<sup>9</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff10">
<sup>10</sup>
Cardiology University Department, IRCCS Policlinico San Donato, Piazza Edmondo Malan, Milan 20097, Italy</div>
<div id="aff11">
<sup>11</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff12">
<sup>12</sup>
Cardiology University Department, IRCCS Policlinico San Donato, Piazza Edmondo Malan, Milan 20097, Italy</div>
<div id="aff13">
<sup>13</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff14">
<sup>14</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff15">
<sup>15</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff16">
<sup>16</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff17">
<sup>17</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff18">
<sup>18</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff19">
<sup>19</sup>
Health Science Interdisciplinary Center, Scuola Superiore Sant’Anna, Via Giuseppe Moruzzi, Pisa 56127, Italy</div>
<div id="aff20">
<sup>20</sup>
Cardiovascular Department, Fondazione Toscana Gabriele Monasterio, Via Giuseppe Moruzzi, Pisa 56124, Italy</div>
<div id="aff21">
<sup>21</sup>
Biostatistics Unit, University College London Eastman Dental Institute, 256 Grays Inn Road, London WC1X 8LD, UK</div>
<div id="aff22">
<sup>22</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff23">
<sup>23</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff24">
<sup>24</sup>
BHF Cardiovascular Research Centre, University of Glasgow, 126 University Pl, Glasgow G12 8TA, UK</div>
<div id="aff25">
<sup>25</sup>
Institute of Cardiovascular Science, University College London, 1–19 Torrington Place, London WC1E 7HB, UK</div>
<div id="aff26">
<sup>26</sup>
University College London, London, UK</div>
<div id="aff27">
<sup>27</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff28">
<sup>28</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff29">
<sup>29</sup>
BHF Cardiovascular Research Centre, University of Glasgow, 126 University Pl, Glasgow G12 8TA, UK</div>
<div id="aff30">
<sup>30</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div id="aff31">
<sup>31</sup>
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK</div>
<div class="author-notes p">
<div class="fn" id="ehad347-cor1">
<sup>✉</sup><p class="display-inline">Corresponding author. Tel: +44 20 7433 2764, Fax: +44 20 7433 2803, Email: <span>m.fontana@ucl.ac.uk</span></p>
</div>
<div class="fn" id="ehad347-FM1">
<sup>b</sup><p class="display-inline">Joint first authors.</p>
</div>
<div class="fn" id="ehad347-FM2">
<sup>c</sup><p class="display-inline">Joint last authors.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2023 Jan 5; Revised 2023 May 9; Accepted 2023 May 19; Collection date 2023 Aug 14.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.</div>
<p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by/4.0/</a>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC10424879  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37216684/" class="usa-link">37216684</a>
</div>
<div class="ra xbox p" role="complementary" aria-label="Related or updated information about this article">
<div>See "<a href="https://pubmed.ncbi.nlm.nih.gov/37224517/" class="usa-link">Neurohormonal blockade in transthyretin amyloidosis, perhaps one size does not fit all?</a>" with doi: 10.1093/eurheartj/ehad357.</div>
<div>
<strong>This article has been corrected.</strong> See <a href="/articles/PMC10998728/" class="usa-link">Eur Heart J. 2024 Mar 1;45(14):1251</a>.</div>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="s1"><h3 class="pmc_sec_title">Aims</h3>
<p>The aims of this study were to assess prescription patterns, dosages, discontinuation rates, and association with prognosis of conventional heart failure medications in patients with transthyretin cardiac amyloidosis (ATTR-CA).</p></section><section id="s2"><h3 class="pmc_sec_title">Methods and results</h3>
<p>A retrospective analysis of all consecutive patients diagnosed with ATTR-CA at the National Amyloidosis Centre between 2000 and 2022 identified 2371 patients with ATTR-CA. Prescription of heart failure medications was greater among patients with a more severe cardiac phenotype, comprising beta-blockers in 55.4%, angiotensin-converting enzyme inhibitors (ACEis)/angiotensin II receptor blockers (ARBs) in 57.4%, and mineralocorticoid receptor antagonists (MRAs) in 39.0% of cases. During a median follow-up of 27.8 months (interquartile range 10.6–51.3), 21.7% had beta-blockers discontinued, and 32.9% had ACEi/ARBs discontinued. In contrast, only 7.5% had MRAs discontinued. A propensity score-matched analysis demonstrated that treatment with MRAs was independently associated with a reduced risk of mortality in the overall population [hazard ratio (HR) 0.77 (95% confidence interval (CI) 0.66–0.89), <em>P</em> &lt; .001] and in a pre-specified subgroup of patients with a left ventricular ejection fraction (LVEF) &gt;40% [HR 0.75 (95% CI 0.63–0.90), <em>P</em> = .002]; and treatment with low-dose beta-blockers was independently associated with a reduced risk of mortality in a pre-specified subgroup of patients with a LVEF ≤40% [HR 0.61 (95% CI 0.45–0.83), <em>P</em> = .002]. No convincing differences were found for treatment with ACEi/ARBs.</p></section><section id="s3"><h3 class="pmc_sec_title">Conclusion</h3>
<p>Conventional heart failure medications are currently not widely prescribed in ATTR-CA, and those that received medication had more severe cardiac disease. Beta-blockers and ACEi/ARBs were often discontinued, but low-dose beta-blockers were associated with reduced risk of mortality in patients with a LVEF ≤40%. In contrast, MRAs were rarely discontinued and were associated with reduced risk of mortality in the overall population; but these findings require confirmation in prospective randomized controlled trials.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> Cardiac ATTR amyloidosis, Heart failure, Heart failure medications, Beta-blockers, Mineralocorticoid receptor antagonists</p></section></section><section class="abstract" id="abstract2"><h2>Structured Graphical Abstract</h2>
<figure class="fig xbox font-sm" id="ehad347-ehad347_ga1"><h3 class="obj_head">Structured Graphical Abstract.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10424879_ehad347_ga1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ede/10424879/94276dfa638a/ehad347_ga1.jpg" loading="lazy" height="670" width="700" alt="Structured Graphical Abstract"></a></p>
<div class="p text-right font-secondary"><a href="figure/ehad347-ehad347_ga1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Discontinuation rates of heart failure medications in patients with cardiac ATTR amyloidosis. Kaplan–Meier curves comparing survival in patients treated with heart failure medications to propensity score-matched patients not treated with heart failure medications, followed by a Cox proportional hazards regression analysis. ACEi, angiotensin-converting enzyme inhibitor; ARBs, angiotensin II receptor blockers; MRAs, mineralocorticoid receptor antagonists; LVEF, left ventricular ejection fraction; HR, hazard ratio; CI, confidence interval.</p></figcaption></figure></section><hr class="headless">
<p>
<strong>See the editorial comment for this article ‘Neurohormonal blockade in transthyretin amyloidosis: perhaps one size does not fit all?’, by R.K. Cheng and S.A.M. Cuddy, <a href="https://doi.org/10.1093/eurheartj/ehad357" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1093/eurheartj/ehad357</a>.</strong>
</p>
<section id="ehad347-s0"><h2 class="pmc_sec_title">Introduction</h2>
<p>Transthyretin cardiac amyloidosis (ATTR-CA) causes progressive, fatal, heart failure (HF), due to misfolding of transthyretin (TTR), forming insoluble amyloid fibrils, which are deposited within the myocardial extracellular space.<sup><a href="#ehad347-B1" class="usa-link" aria-describedby="ehad347-B1">1</a>,<a href="#ehad347-B2" class="usa-link" aria-describedby="ehad347-B2">2</a></sup> Until recently, ATTR-CA was considered a rare, untreatable disease. However, improvements in diagnostics coupled with emerging high-cost therapies are challenging these long-held beliefs. The ATTR-CA is far more common than previously suspected, and there is a potential for successful therapeutic intervention.<sup><a href="#ehad347-B3" class="usa-link" aria-describedby="ehad347-B3">3</a></sup></p>
<p>The only drug proved to be associated with prognostic benefit in ATTR-CA is tafamidis, which is a highly specific drug that targets the circulating TTR protein and stabilizes the TTR tetramer to prevent dissociation into amyloidogenic monomers that deposit in the myocardium, causing an infiltrative and restrictive cardiomyopathy. Tafamidis was shown in a phase 3 placebo-controlled trial (ATTR-ACT) to reduce the combined primary endpoint of cardiovascular hospitalizations and mortality.<sup><a href="#ehad347-B4" class="usa-link" aria-describedby="ehad347-B4">4</a></sup> However, unfortunately, the high cost associated with tafamidis has resulted in restricted use, and tafamidis has not been approved for the treatment of ATTR-CA in many countries.<sup><a href="#ehad347-B5" class="usa-link" aria-describedby="ehad347-B5">5</a></sup></p>
<p>At present, it is unknown whether conventional HF medications that have substantial benefits in patients with HF of other aetiologies may also benefit those with ATTR-CA, as patients with known ATTR-CA have been excluded from previous HF trials.<sup><a href="#ehad347-B6" class="usa-link" aria-describedby="ehad347-B6">6–13</a></sup> Hence, the value of conventional HF medications in patients with ATTR-CA is still debated. Small-scale studies have yielded contrasting results, with some suggesting that low doses of conventional HF medications are well tolerated,<sup><a href="#ehad347-B14" class="usa-link" aria-describedby="ehad347-B14">14</a>,<a href="#ehad347-B15" class="usa-link" aria-describedby="ehad347-B15">15</a></sup> while others reported that not only are these medications poorly tolerated, but they may result in worse outcomes.<sup><a href="#ehad347-B16" class="usa-link" aria-describedby="ehad347-B16">16</a>,<a href="#ehad347-B17" class="usa-link" aria-describedby="ehad347-B17">17</a></sup> The lack of large-scale clinical trials has resulted in a significant knowledge gap, although a position statement from the European Society of Cardiology (ESC) working group on myocardial and pericardial diseases regarding HF medications in ATTR-CA recommends stopping beta-blockers, and avoiding angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs), and are silent about mineralocorticoid receptor antagonists (MRAs).<sup><a href="#ehad347-B18" class="usa-link" aria-describedby="ehad347-B18">18</a></sup></p>
<p>The aims of this study were to: (i) assess the prescription pattern of conventional HF medications in patients with ATTR-CA; (ii) assess the dosages and discontinuation rates of HF medications in patients with ATTR-CA; and (iii) assess the association between treatment with HF medications and survival in patients with ATTR-CA.</p></section><section id="ehad347-s1"><h2 class="pmc_sec_title">Methods</h2>
<p>Consecutive patients in whom a diagnosis of ATTR-CA was confirmed at the National Amyloidosis Centre (NAC), between January 2000 and September 2022, were included. Patients with evidence of ATTR-polyneuropathy were excluded, as many have autonomic neuropathy and are not treated with HF medications due to concomitant postural hypotension.</p>
<p>Between 2000 and 2005 the diagnosis of ATTR-CA was established based on HF symptoms together with a characteristic CA echocardiogram and either direct endomyocardial biopsy proof of ATTR-amyloid or ATTR-amyloid in an extra-cardiac biopsy. From 2006 onwards cardiac magnetic resonance was added to the assessment if there was diagnostic doubt. From 2010 onwards, <sup>99m</sup>Technetium labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (<sup>99m</sup>Tc-DPD) scintigraphy was utilized, and diagnosis established based on ATTR-amyloid in an extra-cardiac biopsy with cardiac uptake on <sup>99m</sup>Tc-DPD scintigraphy; or grade 2–3 cardiac uptake on <sup>99m</sup>Tc-DPD scintigraphy in the absence of biochemical evidence of a plasma cell dyscrasia. All patients underwent genetic sequencing of the <em>TTR</em> gene and provided written consent for their data to be retrospectively analysed and published, in line with the Declaration of Helsinki and approval from the Royal Free Hospital ethics committee (REC 21/PR/0620).</p>
<p>All patients are enrolled into a protocolized follow-up program that consists of 6–12 monthly consultations. Data regarding whether HF medications were initiated, continued, or stopped, and medication dosages were all recorded. Medication classes were defined based on the ESC HF guidelines and comprised beta-blockers, ACEi/ARBs and MRAs. Target doses from the guidelines enabled comparisons by converting the daily dose to a percentage of the target dose. Medication classes were recorded regardless of whether the specific drug had been used in previous HF trials.<sup><a href="#ehad347-B19" class="usa-link" aria-describedby="ehad347-B19">19</a></sup> Management decisions utilized a combined decision-making process involving local clinicians and the NAC team. Considering the knowledge gap, decisions concerning the initiation or discontinuation of HF medications were made following each clinical assessment on a case-by-case basis.</p>
<section id="ehad347-s1.1"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p>Statistical analysis was performed using Stata (StataCorp. 2021. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC). All continuous variables were tested for normality (Shapiro–Wilk test) and presented as mean ± standard deviation if the distribution was normal or median [interquartile range (IQR)] otherwise, other than N-terminal pro-B-type natriuretic peptide (NT-proBNP) which was log-transformed for bivariate testing. The independent sample <em>t-</em>test was used to compare means if the data were normally distributed in each treatment group, or its non-parametric equivalent was used to compare the distributions of the two treatment groups. One-way analysis of variance if the data were normally distributed in each treatment group was used to compare means in more than two groups; or its non-parametric equivalent was used to compare the distributions of multiple groups. A significant result was followed by <em>post hoc</em> Bonferroni corrected pairwise comparisons to establish where differences lay. Categorical data are presented as absolute numbers and frequencies (%) and compared using the χ<sup>2</sup> test.</p>
<p>All mortality data were obtained via the UK Office of National Statistics, which is the formal government registry for all deaths throughout the UK. The mortality endpoint was defined as time to death from date of diagnosis for all deceased patients and time to censor date (25 October 2022) from date of diagnosis among the remainder. Follow-up was restricted to ≤60 months, after which patients were censored due to the majority of events occurring in the first 60 months, and a low number of patients at risk after 60 months. To account for amyloid-specific disease-modifying therapy or clinical trials, patients were censored at their start date.</p>
<p>Survival was evaluated using Cox proportional hazards regression analysis, providing estimated hazard ratios (HRs) with 95% confidence intervals (CIs). The proportional hazards assumption was checked and confirmed using weighted Schoenfeld residuals. With regard to the survival analysis, patients were classed as being treated with HF medications if they were treated continuously for at least 6 months following their initial assessment, or an event occurred within the first 6 months while patients were continuously treated. If the medication was stopped during the first 6 months, then patients were classed as not taking the medication. The initial survival analysis was performed on the whole study population using a multivariable Cox proportional hazards regression adjusting for covariates selected <em>a priori</em> based on clinical relevance, association with HF medication treatment and association with survival [age, sex, ischaemic heart disease (IHD), diabetes mellitus, hypertension, atrial fibrillation, NAC disease stage, wild-type or hereditary ATTR-CA, interventricular septal thickness in diastole (IVSd), longitudinal strain, beta-blocker, ACEi/ARBs, and MRAs].</p>
<p>Propensity score (PS) matching is widely used to reduce confounding biases in observational studies. The PS is a score between 0 and 1 that reflects the likelihood of the patient receiving one of the HF medications of interest conditional on a set of variables, so that those with similar PSs are independent of these variables. Prior to PS matching, missing data were replaced using single imputation, whereby missing values of numerical variables were replaced by the relevant median, and missing values of categorical variables were replaced by the relevant mode, to overcome potential bias introduced by excluding patients with missing data. In order to compare two particular HF medications, a PS for each individual was determined using all the aforementioned variables, apart from the HF medications being assessed. After finding the area of common support (in which the histograms of the PSs overlapped), the patients were then matched on the basis of their PSs in the two medication groups in a 1:1 ratio using the nearest neighbour approach without replacement and calliper width equal to 0.20 times the standard deviation of the logit of the PSs. The adequacy of matching was verified by ensuring that the standardized differences between groups were &lt;0.10 for all variables used to create the PS. A Cox proportional hazards regression model was then applied using the matched groups to compare the effect on survival of the two medications of interest. Additional PS-matched analyses specified <em>a priori</em> were carried out in the subgroup of patients with a left ventricular ejection fraction (LVEF) ≤40% and the subgroup of patients with a LVEF &gt;40% (based on the guideline definition for HF with reduced ejection fraction being a LVEF ≤40%).<sup><a href="#ehad347-B19" class="usa-link" aria-describedby="ehad347-B19">19</a></sup> Kaplan–Meier curves were constructed with statistical significance being assessed with a log-rank test. Significant results were followed by sensitivity analyses to assess whether these results could be replicated; firstly using an ‘intention to treat’ approach whereby patients were classed as treated, or not treated based on their treatment status at diagnosis (rather than over the first 6 months), secondly without censoring patients for the start date of clinical trials or disease-modifying therapy, and lastly analysing the medication use as a time-varying exposure. Statistical significance was defined as <em>P</em> &lt; .05.</p></section></section><section id="ehad347-s2"><h2 class="pmc_sec_title">Results</h2>
<p>We identified 2371 patients diagnosed with ATTR-CA. The population compromised 1840 (77.6%) with wild-type ATTR-CA and 531 (22.4%) with hereditary ATTR-CA. The mean age of patients was 77.5 ± 7.3 years, and 90.0% were men. About two-thirds of patients were in New York Heart Association (NYHA) classes I and II, the median NT-proBNP was 2925 ng/L, and the mean LVEF was 48.2% [531 (22.4%) had a LVEF ≤40%). Most patients were in NAC stages 1 (45.8%) or 2 (36.0%). Approximately half of the patients had concomitant atrial fibrillation/flutter, and 54.2% had an estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m<sup>2</sup>. Overall, 1955 patients (82.4%) were treated with a diuretic. In most cases (76.8% patients) a loop diuretic was prescribed either alone or in combination (<em><a href="#ehad347-T1" class="usa-link">Table 1</a></em>). A total of 467 (19.7%) patients were enrolled into clinical trials, or treated with disease-modifying therapy (clinical trials, <em>n</em> = 377; tafamidis, <em>n</em> = 90). These patients were younger and had a milder cardiac phenotype at diagnosis than the rest of the study population (see <a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Table S1</a></em>).</p>
<section class="tw xbox font-sm" id="ehad347-T1"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>Baseline characteristics and echocardiographic parameters for the overall population, and for patients separated into those with a LVEF &gt;40% and a LVEF ≤40%</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col valign="top" align="left" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1">Baseline characteristics</th>
<th align="center" rowspan="1" colspan="1">Overall study population (<em>n</em> = 2371)</th>
<th align="center" rowspan="1" colspan="1">Patients with a LVEF &gt;40% (<em>n</em> = 1840)</th>
<th align="center" rowspan="1" colspan="1">Patients with a LVEF ≤40% (<em>n</em> = 531)</th>
<th align="center" rowspan="1" colspan="1">
<em>P</em>-value</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">Age</td>
<td rowspan="1" colspan="1">77.5 ± 7.3</td>
<td rowspan="1" colspan="1">77.6 ± 7.3</td>
<td rowspan="1" colspan="1">76.9 ± 7.3</td>
<td rowspan="1" colspan="1">.035</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Sex (male)</td>
<td rowspan="1" colspan="1">2110 (90.0%)</td>
<td rowspan="1" colspan="1">1637 (89.0%)</td>
<td rowspan="1" colspan="1">473 (89.1%)</td>
<td rowspan="1" colspan="1">.943</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Ethnicity</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Caucasian</td>
<td rowspan="1" colspan="1">1893 (79.8%)</td>
<td rowspan="1" colspan="1">1525 (82.9%)<a href="#ehad347-tblfn3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">368 (69.3%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Afro-Caribbean</td>
<td rowspan="1" colspan="1">444 (18.7%)</td>
<td rowspan="1" colspan="1">288 (15.7%)<a href="#ehad347-tblfn3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">156 (29.4%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Asian</td>
<td rowspan="1" colspan="1">22 (0.9%)</td>
<td rowspan="1" colspan="1">18 (1.0%)</td>
<td rowspan="1" colspan="1">4 (0.8%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Other</td>
<td rowspan="1" colspan="1">12 (0.5%)</td>
<td rowspan="1" colspan="1">9 (0.5%)</td>
<td rowspan="1" colspan="1">3 (0.6%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">wtATTR</td>
<td rowspan="1" colspan="1">1840 (77.6%)</td>
<td rowspan="1" colspan="1">1487 (80.8%)</td>
<td rowspan="1" colspan="1">353 (66.5%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">hATTR</td>
<td rowspan="1" colspan="1">531 (22.4%)</td>
<td rowspan="1" colspan="1">353 (19.2%)</td>
<td rowspan="1" colspan="1">178 (33.5%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">AF/flutter</td>
<td rowspan="1" colspan="1">1223 (51.6%)</td>
<td rowspan="1" colspan="1">937 (50.9%)</td>
<td rowspan="1" colspan="1">286 (53.9%)</td>
<td rowspan="1" colspan="1">.233</td>
</tr>
<tr>
<td rowspan="1" colspan="1">IHD</td>
<td rowspan="1" colspan="1">476 (20.1%)</td>
<td rowspan="1" colspan="1">374 (20.3%)</td>
<td rowspan="1" colspan="1">102 (19.2%)</td>
<td rowspan="1" colspan="1">.571</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Diabetes mellitus</td>
<td rowspan="1" colspan="1">374 (15.8%)</td>
<td rowspan="1" colspan="1">273 (14.8%)</td>
<td rowspan="1" colspan="1">101 (19.0%)</td>
<td rowspan="1" colspan="1">.020</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Hypertension</td>
<td rowspan="1" colspan="1">828 (34.9%)</td>
<td rowspan="1" colspan="1">631 (34.3%)</td>
<td rowspan="1" colspan="1">197 (37.1%)</td>
<td rowspan="1" colspan="1">.232</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Stroke/TIA</td>
<td rowspan="1" colspan="1">109 (4.6%)</td>
<td rowspan="1" colspan="1">182 (9.9%)</td>
<td rowspan="1" colspan="1">76 (14.3%)</td>
<td rowspan="1" colspan="1">.004</td>
</tr>
<tr>
<td rowspan="1" colspan="1">CKD stages 3–5</td>
<td rowspan="1" colspan="1">1288 (54.3%)</td>
<td rowspan="1" colspan="1">953 (51.8%)</td>
<td rowspan="1" colspan="1">335 (63.1%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Cardiac devices</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">PPM</td>
<td rowspan="1" colspan="1">214 (9.0%)</td>
<td rowspan="1" colspan="1">173 (9.4%)</td>
<td rowspan="1" colspan="1">41 (7.7%)</td>
<td rowspan="1" colspan="1">.234</td>
</tr>
<tr>
<td rowspan="1" colspan="1">ICD</td>
<td rowspan="1" colspan="1">46 (1.9%)</td>
<td rowspan="1" colspan="1">29 (1.6%)</td>
<td rowspan="1" colspan="1">17 (3.2%)</td>
<td rowspan="1" colspan="1">.017</td>
</tr>
<tr>
<td rowspan="1" colspan="1">CRT-D</td>
<td rowspan="1" colspan="1">23 (1.0%)</td>
<td rowspan="1" colspan="1">14 (0.8%)</td>
<td rowspan="1" colspan="1">9 (1.7%)</td>
<td rowspan="1" colspan="1">.053</td>
</tr>
<tr>
<td rowspan="1" colspan="1">CRT-P</td>
<td rowspan="1" colspan="1">37 (1.6%)</td>
<td rowspan="1" colspan="1">24 (1.3%)</td>
<td rowspan="1" colspan="1">13 (2.4%)</td>
<td rowspan="1" colspan="1">.061</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Heart failure severity</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">NYHA class</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 1</td>
<td rowspan="1" colspan="1">317 (13.4%)</td>
<td rowspan="1" colspan="1">280 (15.2%)<a href="#ehad347-tblfn3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">37 (7.0%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 2</td>
<td rowspan="1" colspan="1">1387 (58.5%)</td>
<td rowspan="1" colspan="1">1093 (59.4%)<a href="#ehad347-tblfn3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">294 (55.4%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 3</td>
<td rowspan="1" colspan="1">435 (18.3%)</td>
<td rowspan="1" colspan="1">279 (15.2%)<a href="#ehad347-tblfn3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">156 (29.4%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 4</td>
<td rowspan="1" colspan="1">30 (1.3%)</td>
<td rowspan="1" colspan="1">19 (1.0%)</td>
<td rowspan="1" colspan="1">11 (2.1%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Missing</td>
<td rowspan="1" colspan="1">202</td>
<td rowspan="1" colspan="1">169</td>
<td rowspan="1" colspan="1">33</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">NAC stage</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 1</td>
<td rowspan="1" colspan="1">1086 (45.8%)</td>
<td rowspan="1" colspan="1">926 (50.3%)<a href="#ehad347-tblfn3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">160 (30.1%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 2</td>
<td rowspan="1" colspan="1">853 (36.0%)</td>
<td rowspan="1" colspan="1">613 (33.3%)<a href="#ehad347-tblfn3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">240 (45.2%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 3</td>
<td rowspan="1" colspan="1">395 (16.7%)</td>
<td rowspan="1" colspan="1">266 (14.5%)<a href="#ehad347-tblfn3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">129 (24.3%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Missing</td>
<td rowspan="1" colspan="1">37</td>
<td rowspan="1" colspan="1">35</td>
<td rowspan="1" colspan="1">2</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">NT-proBNP (ng/L)</td>
<td rowspan="1" colspan="1">2925 (1530–5321)</td>
<td rowspan="1" colspan="1">2597 (1394–4786)</td>
<td rowspan="1" colspan="1">4123 (2484–7201)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">eGFR (mL/min/1.73 m²)</td>
<td rowspan="1" colspan="1">58 (46–71)</td>
<td rowspan="1" colspan="1">59 (47–72)</td>
<td rowspan="1" colspan="1">54 (43–66)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">6-Min walk test (meters)</td>
<td rowspan="1" colspan="1">347 (247–430)</td>
<td rowspan="1" colspan="1">354 (256–436)</td>
<td rowspan="1" colspan="1">322 (216–407)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">6-Min walk test (% predicted)</td>
<td rowspan="1" colspan="1">71.2 ± 26.5</td>
<td rowspan="1" colspan="1">72.9 ± 25.7</td>
<td rowspan="1" colspan="1">64.7 ± 28.3</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td>
<td rowspan="1" colspan="1">125.1 ± 21.4</td>
<td rowspan="1" colspan="1">126.3 ± 22.1</td>
<td rowspan="1" colspan="1">121.3 ± 18.7</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td>
<td rowspan="1" colspan="1">74.4 ± 12.7</td>
<td rowspan="1" colspan="1">73.9 ± 12.8</td>
<td rowspan="1" colspan="1">75.9 ± 12.4</td>
<td rowspan="1" colspan="1">.020</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Heart rate (b.p.m.)</td>
<td rowspan="1" colspan="1">72.2 ± 13.7</td>
<td rowspan="1" colspan="1">71.1 ± 13.2</td>
<td rowspan="1" colspan="1">75.8 ± 14.4</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Echocardiographic parameters</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">IVSd (mm)</td>
<td rowspan="1" colspan="1">16.9 ± 2.4</td>
<td rowspan="1" colspan="1">16.9 ± 2.4</td>
<td rowspan="1" colspan="1">17.0 ± 2.4</td>
<td rowspan="1" colspan="1">.321</td>
</tr>
<tr>
<td rowspan="1" colspan="1">PWTd (mm)</td>
<td rowspan="1" colspan="1">16.3 ± 2.5</td>
<td rowspan="1" colspan="1">16.3 ± 2.5</td>
<td rowspan="1" colspan="1">16.4 ± 2.6</td>
<td rowspan="1" colspan="1">.220</td>
</tr>
<tr>
<td rowspan="1" colspan="1">MWT (mm)</td>
<td rowspan="1" colspan="1">17.1 ± 2.4</td>
<td rowspan="1" colspan="1">17.1 ± 2.4</td>
<td rowspan="1" colspan="1">17.2 ± 2.4</td>
<td rowspan="1" colspan="1">.326</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Left atrial area (cm<sup>2</sup>)</td>
<td rowspan="1" colspan="1">26.2 ± 5.5</td>
<td rowspan="1" colspan="1">26.1 ± 5.5</td>
<td rowspan="1" colspan="1">26.6 ± 6.4</td>
<td rowspan="1" colspan="1">.069</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Right atrial area (cm<sup>2</sup>)</td>
<td rowspan="1" colspan="1">24.5 ± 6.5</td>
<td rowspan="1" colspan="1">23.9 ± 6.4</td>
<td rowspan="1" colspan="1">26.3 ± 6.4</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Stroke volume (mL)</td>
<td rowspan="1" colspan="1">37.3 ± 13.9</td>
<td rowspan="1" colspan="1">39.9 ± 13.8</td>
<td rowspan="1" colspan="1">29.4 ± 10.9</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Simpson’s biplane LVEF (%)</td>
<td rowspan="1" colspan="1">48.2 ± 10.6</td>
<td rowspan="1" colspan="1">52.7 ± 7.2</td>
<td rowspan="1" colspan="1">33.6 ± 5.3</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Longitudinal strain (%)</td>
<td rowspan="1" colspan="1">−10.8 ± 3.6</td>
<td rowspan="1" colspan="1">−11.7 ± 3.5</td>
<td rowspan="1" colspan="1">−8.1 ± 2.6</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">TAPSE (mm)</td>
<td rowspan="1" colspan="1">15.1 ± 4.9</td>
<td rowspan="1" colspan="1">15.9 ± 4.9</td>
<td rowspan="1" colspan="1">12.6 ± 3.5</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">E/e′</td>
<td rowspan="1" colspan="1">16.8 ± 6.4</td>
<td rowspan="1" colspan="1">16.5 ± 6.2</td>
<td rowspan="1" colspan="1">17.8 ± 7.0</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Medications</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Beta-blockers</td>
<td rowspan="1" colspan="1">1313 (55.4%)</td>
<td rowspan="1" colspan="1">971 (52.8%)</td>
<td rowspan="1" colspan="1">342 (64.4%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">ACEi/ARBs</td>
<td rowspan="1" colspan="1">1362 (57.4%)</td>
<td rowspan="1" colspan="1">1041 (56.6%)</td>
<td rowspan="1" colspan="1">321 (60.5%)</td>
<td rowspan="1" colspan="1">.112</td>
</tr>
<tr>
<td rowspan="1" colspan="1">MRAs</td>
<td rowspan="1" colspan="1">925 (39.0%)</td>
<td rowspan="1" colspan="1">673 (36.6%)</td>
<td rowspan="1" colspan="1">252 (47.5%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Loop diuretics</td>
<td rowspan="1" colspan="1">1808 (76.8%)</td>
<td rowspan="1" colspan="1">1357 (74.3%)</td>
<td rowspan="1" colspan="1">451 (85.3%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/ehad347-T1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="ehad347-tblfn1"><p>Patients with hATTR-CA had the following variants: p.(Val142Ile) = 392, p.(Thr80Ala) = 93, p.(Ile127Val) = 12, p.(Ile88Leu) = 6, p.(Ser97Tyr) = 6, p.(Glu62Asp) = 4, p.(Glu109Lys) = 3, p.(Gly26Ser) = 3, p.(Val40Ile) = 2, p.(Val50Met) = 2, p.(Ala56Pro) = 1, p.(Asp58Tyr) = 1, p.(Asp58Val) = 1, p.(Asp59Val) = 1, p.(Glu74Gln) = 1, p.(Glu74Gly) = 1, p.(Glu74Leu) = 1, and p.(Phe64Leu) = 1.</p></div>
<div class="fn" id="ehad347-tblfn2"><p>AF, atrial fibrillation; IHD, ischaemic heart disease; TIA, transient ischaemic attack; CKD, chronic kidney disease; PPM, permanent pacemaker; ICD, implantable cardioverter defibrillator; CRT-D, cardiac resynchronization therapy defibrillator; CRT-P, cardiac resynchronization therapy pacemaker; NYHA, New York Heart Association; NAC, National Amyloidosis Centre; NT-proBNP, N-terminal pro B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; IVSd, interventricular septum in diastole; PWTd, posterior wall thickness in diastole; MWT, maximal wall thickness; LVEF, left ventricular ejection fraction; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; MRA, mineralocorticoid receptor antagonist.</p></div>
<div class="fn" id="ehad347-tblfn3"><p>
<em>P</em> &lt; .05.</p></div>
</div></section><section id="ehad347-s2.1"><h3 class="pmc_sec_title">Prescription pattern of heart failure medications</h3>
<section id="ehad347-s2.1.1"><h4 class="pmc_sec_title">Beta-blockers</h4>
<p>A total of 1313 (55.4%) patients were treated with beta-blockers (64.4% in patients with a LVEF ≤40%) at diagnosis. Those treated with beta-blockers had a higher prevalence of IHD, diabetes mellitus, and atrial fibrillation compared to patients not receiving this type of treatment. Those treated with beta-blockers had a more severe cardiac phenotype, with a worse functional capacity as evidenced by NYHA class and 6-min walk test (6MWT), and a higher NAC disease stage [a greater proportion of patients had stage 3 (severe) disease]. The median NT-proBNP among patients treated with beta-blockers was significantly higher, while median eGFR was significantly lower than patients not receiving beta-blockers. Patients treated with beta-blockers had a larger bi-atrial size, lower LVEF, lower tricuspid annular plane systolic excursion (TAPSE), and worse longitudinal strain than those not receiving this type of treatment.</p></section><section id="ehad347-s2.1.2"><h4 class="pmc_sec_title">Renin-angiotensin system blockers</h4>
<p>A total of 1362 (57.4%) patients were treated with an ACEi or ARB (60.5% in patients with a LVEF ≤40%) at diagnosis. As for beta-blockers, those treated with ACEi/ARBs had a higher prevalence of IHD, diabetes mellitus, and atrial fibrillation compared to patients not receiving this type of treatment. In addition, patients treated with an ACEi/ARB were more likely to have hypertension than patients not receiving this type of treatment. Those treated with ACEi/ARBs had a severe cardiac phenotype, with a higher NYHA class and NAC disease stage, and a higher proportion of patients having chronic kidney disease stages 3–5 than patients not receiving ACEi/ARBs. Patients treated with ACEi/ARBs had a larger bi-atrial size, lower LVEF, and worse longitudinal strain than those not receiving this type of treatment.</p></section><section id="ehad347-s2.1.3"><h4 class="pmc_sec_title">Mineralocorticoid receptor antagonists</h4>
<p>A total of 925 (39.0%) patients were treated with an MRA (47.5% in patients with a LVEF ≤40%) at diagnosis. Those treated with MRAs had a higher prevalence of diabetes mellitus and atrial fibrillation but, unlike beta-blocker and ACEi/ARB treatment, patients treated with an MRA did not have more IHD. Those treated with MRAs had a more severe cardiac phenotype, with a worse functional capacity as evidenced by NYHA class and 6MWT, and a higher NAC disease. The median NT-proBNP among patients treated with MRAs was significantly higher, while median eGFR was significantly lower than patients not receiving MRAs. Patients treated with MRAs had a larger right atrial area, lower stroke volume, lower LVEF, lower TAPSE, higher E/e′, and worse longitudinal strain than those not receiving this type of treatment (<em><a href="#ehad347-T2" class="usa-link">Table 2</a></em>).</p>
<section class="tw xbox font-sm" id="ehad347-T2"><h5 class="obj_head">Table 2.</h5>
<div class="caption p"><p>Baseline characteristics and echocardiographic parameters for patients treated with heart failure medications compared to patients not treated with heart failure medications</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col valign="top" align="left" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2" colspan="1">Variables</th>
<th align="center" colspan="3" rowspan="1">Patients with cardiac ATTR amyloidosis split by treatment with beta-blockers</th>
<th align="center" colspan="3" rowspan="1">Patients with cardiac ATTR amyloidosis split by treatment with ACEi/ARBs</th>
<th align="center" colspan="3" rowspan="1">Patients with cardiac ATTR amyloidosis split by treatment with MRAs</th>
</tr>
<tr>
<th align="center" rowspan="1" colspan="1">Patients treated with beta-blockers (<em>n</em> = 1313, 55.4%)</th>
<th align="center" rowspan="1" colspan="1">Patients not treated with beta-blockers (<em>n</em> = 1058, 44.6%)</th>
<th align="center" rowspan="1" colspan="1">
<em>P</em>-value</th>
<th align="center" rowspan="1" colspan="1">Patients treated with ACEi/ARB (<em>n</em> = 1362, 57.4%)</th>
<th align="center" rowspan="1" colspan="1">Patients not treated with ACEi/ARB (<em>n</em> = 1009, 42.6%)</th>
<th align="center" rowspan="1" colspan="1">
<em>P</em>-value</th>
<th align="center" rowspan="1" colspan="1">Patients treated with MRAs (<em>n</em> = 925, 39.0%)</th>
<th align="center" rowspan="1" colspan="1">Patients not treated with MRAs (<em>n</em> = 1446, 61.0%)</th>
<th align="center" rowspan="1" colspan="1">
<em>P</em>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">Baseline characteristics</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Age</td>
<td rowspan="1" colspan="1">77.4 ± 6.9</td>
<td rowspan="1" colspan="1">77.6 ± 7.7</td>
<td rowspan="1" colspan="1">.456</td>
<td rowspan="1" colspan="1">77.4 ± 6.7</td>
<td rowspan="1" colspan="1">77.6 ± 8.0</td>
<td rowspan="1" colspan="1">.546</td>
<td rowspan="1" colspan="1">76.9 ± 6.9</td>
<td rowspan="1" colspan="1">77.9 ± 7.5</td>
<td rowspan="1" colspan="1">.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Sex (male)</td>
<td rowspan="1" colspan="1">1172 (89.3%)</td>
<td rowspan="1" colspan="1">938 (88.7%)</td>
<td rowspan="1" colspan="1">.641</td>
<td rowspan="1" colspan="1">1224 (89.9%)</td>
<td rowspan="1" colspan="1">886 (87.8%)</td>
<td rowspan="1" colspan="1">.113</td>
<td rowspan="1" colspan="1">824 (89.1%)</td>
<td rowspan="1" colspan="1">1286 (88.9%)</td>
<td rowspan="1" colspan="1">.912</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Ethnicity</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">.016</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">.040</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Caucasian</td>
<td rowspan="1" colspan="1">1030 (78.4%)</td>
<td rowspan="1" colspan="1">863 (81.6%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">1069 (78.5%)</td>
<td rowspan="1" colspan="1">824 (81.7%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">695 (75.1%)*</td>
<td rowspan="1" colspan="1">1198 (82.8%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Afro-Caribbean</td>
<td rowspan="1" colspan="1">269 (20.5%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">175 (16.5%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">278 (20.4%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">166 (16.5%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">215 (23.2%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">229 (15.8%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Asian</td>
<td rowspan="1" colspan="1">11 (0.8%)</td>
<td rowspan="1" colspan="1">11 (1.0%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">9 (0.7%)</td>
<td rowspan="1" colspan="1">13 (1.3%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">9 (1.0%)</td>
<td rowspan="1" colspan="1">13 (0.9%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Other</td>
<td rowspan="1" colspan="1">3 (0.2%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">9 (0.9%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">6 (0.4%)</td>
<td rowspan="1" colspan="1">6 (0.6%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">6 (0.6%)</td>
<td rowspan="1" colspan="1">6 (0.4%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">wtATTR</td>
<td rowspan="1" colspan="1">1021 (77.8%)</td>
<td rowspan="1" colspan="1">819 (77.4%)</td>
<td rowspan="1" colspan="1">.839</td>
<td rowspan="1" colspan="1">1067 (78.3%)</td>
<td rowspan="1" colspan="1">773 (76.6%)</td>
<td rowspan="1" colspan="1">.318</td>
<td rowspan="1" colspan="1">686 (74.2%)</td>
<td rowspan="1" colspan="1">1154 (79.8%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">hATTR</td>
<td rowspan="1" colspan="1">292 (22.2%)</td>
<td rowspan="1" colspan="1">239 (22.6%)</td>
<td rowspan="1" colspan="1">.839</td>
<td rowspan="1" colspan="1">295 (21.7%)</td>
<td rowspan="1" colspan="1">236 (23.4%)</td>
<td rowspan="1" colspan="1">.318</td>
<td rowspan="1" colspan="1">239 (25.8%)</td>
<td rowspan="1" colspan="1">292 (20.2%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">AF/flutter</td>
<td rowspan="1" colspan="1">755 (57.5%)</td>
<td rowspan="1" colspan="1">468 (44.2%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">728 (53.5%)</td>
<td rowspan="1" colspan="1">495 (49.1%)</td>
<td rowspan="1" colspan="1">.034</td>
<td rowspan="1" colspan="1">515 (55.7%)</td>
<td rowspan="1" colspan="1">708 (49.0%)</td>
<td rowspan="1" colspan="1">.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">IHD</td>
<td rowspan="1" colspan="1">300 (22.8%)</td>
<td rowspan="1" colspan="1">176 (16.6%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">301 (22.1%)</td>
<td rowspan="1" colspan="1">175 (17.3%)</td>
<td rowspan="1" colspan="1">.004</td>
<td rowspan="1" colspan="1">198 (21.4%)</td>
<td rowspan="1" colspan="1">278 (19.2%)</td>
<td rowspan="1" colspan="1">.196</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Diabetes mellitus</td>
<td rowspan="1" colspan="1">241 (18.4%)</td>
<td rowspan="1" colspan="1">133 (12.6%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">249 (18.2%)</td>
<td rowspan="1" colspan="1">125 (12.4%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">168 (18.2%)</td>
<td rowspan="1" colspan="1">206 (14.2%)</td>
<td rowspan="1" colspan="1">.011</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Hypertension</td>
<td rowspan="1" colspan="1">479 (36.5%)</td>
<td rowspan="1" colspan="1">349 (33.0%)</td>
<td rowspan="1" colspan="1">.079</td>
<td rowspan="1" colspan="1">549 (40.3%)</td>
<td rowspan="1" colspan="1">279 (27.7%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">335 (36.2%)</td>
<td rowspan="1" colspan="1">493 (34.1%)</td>
<td rowspan="1" colspan="1">.290</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Stroke/TIA</td>
<td rowspan="1" colspan="1">137 (10.4%)</td>
<td rowspan="1" colspan="1">121 (11.4%)</td>
<td rowspan="1" colspan="1">.436</td>
<td rowspan="1" colspan="1">143 (10.5%)</td>
<td rowspan="1" colspan="1">115 (11.4%)</td>
<td rowspan="1" colspan="1">.487</td>
<td rowspan="1" colspan="1">97 (10.5%)</td>
<td rowspan="1" colspan="1">161 (11.1%)</td>
<td rowspan="1" colspan="1">.670</td>
</tr>
<tr>
<td rowspan="1" colspan="1">CKD stages 3–5</td>
<td rowspan="1" colspan="1">797 (60.7%)</td>
<td rowspan="1" colspan="1">491 (46.4%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">774 (56.8%)</td>
<td rowspan="1" colspan="1">514 (50.9%)</td>
<td rowspan="1" colspan="1">.004</td>
<td rowspan="1" colspan="1">573 (61.9%)</td>
<td rowspan="1" colspan="1">715 (49.4%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Cardiac devices</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">PPM</td>
<td rowspan="1" colspan="1">118 (9.0%)</td>
<td rowspan="1" colspan="1">96 (9.1%)</td>
<td rowspan="1" colspan="1">.942</td>
<td rowspan="1" colspan="1">138 (10.1%)</td>
<td rowspan="1" colspan="1">76 (7.5%)</td>
<td rowspan="1" colspan="1">.029</td>
<td rowspan="1" colspan="1">95 (10.3%)</td>
<td rowspan="1" colspan="1">119 (8.2%)</td>
<td rowspan="1" colspan="1">.091</td>
</tr>
<tr>
<td rowspan="1" colspan="1">ICD</td>
<td rowspan="1" colspan="1">32 (2.4%)</td>
<td rowspan="1" colspan="1">14 (1.3%)</td>
<td rowspan="1" colspan="1">.051</td>
<td rowspan="1" colspan="1">28 (2.1%)</td>
<td rowspan="1" colspan="1">18 (1.8%)</td>
<td rowspan="1" colspan="1">.635</td>
<td rowspan="1" colspan="1">22 (2.4%)</td>
<td rowspan="1" colspan="1">24 (1.7%)</td>
<td rowspan="1" colspan="1">.216</td>
</tr>
<tr>
<td rowspan="1" colspan="1">CRT-D</td>
<td rowspan="1" colspan="1">15 (1.1%)</td>
<td rowspan="1" colspan="1">8 (0.8%)</td>
<td rowspan="1" colspan="1">.340</td>
<td rowspan="1" colspan="1">17 (1.2%)</td>
<td rowspan="1" colspan="1">6 (0.6%)</td>
<td rowspan="1" colspan="1">.108</td>
<td rowspan="1" colspan="1">13 (1.4%)</td>
<td rowspan="1" colspan="1">10 (0.7%)</td>
<td rowspan="1" colspan="1">.084</td>
</tr>
<tr>
<td rowspan="1" colspan="1">CRT-P</td>
<td rowspan="1" colspan="1">21 (1.6%)</td>
<td rowspan="1" colspan="1">16 (1.5%)</td>
<td rowspan="1" colspan="1">.865</td>
<td rowspan="1" colspan="1">23 (1.7%)</td>
<td rowspan="1" colspan="1">14 (1.4%)</td>
<td rowspan="1" colspan="1">.559</td>
<td rowspan="1" colspan="1">21 (2.3%)</td>
<td rowspan="1" colspan="1">16 (1.1%)</td>
<td rowspan="1" colspan="1">.026</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Heart failure severity</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">NYHA class</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 1</td>
<td rowspan="1" colspan="1">135 (10.3%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">182 (17.2%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">143 (10.5%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">174 (17.2%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">87 (9.4%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">230 (15.9%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 2</td>
<td rowspan="1" colspan="1">755 (57.5%)</td>
<td rowspan="1" colspan="1">632 (59.7%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">795 (56.2%)</td>
<td rowspan="1" colspan="1">592 (58.7%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">555 (60.0%)</td>
<td rowspan="1" colspan="1">832 (57.5%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 3</td>
<td rowspan="1" colspan="1">286 (21.8%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">149 (14.1%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">275 (20.2%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">160 (15.9%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">219 (23.7%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">216 (14.9%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 4</td>
<td rowspan="1" colspan="1">18 (1.4%)</td>
<td rowspan="1" colspan="1">12 (1.1%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">20 (1.5%)</td>
<td rowspan="1" colspan="1">10 (1.0%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">15 (1.6%)</td>
<td rowspan="1" colspan="1">15 (1.0%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Missing</td>
<td rowspan="1" colspan="1">119</td>
<td rowspan="1" colspan="1">83</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">129</td>
<td rowspan="1" colspan="1">73</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">49</td>
<td rowspan="1" colspan="1">153</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">NAC stage</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">.047</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 1</td>
<td rowspan="1" colspan="1">524 (40.0%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">562 (52.5%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">607 (44.6%)</td>
<td rowspan="1" colspan="1">479 (47.4%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">379 (41.0%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">707 (48.9%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 2</td>
<td rowspan="1" colspan="1">522 (39.8%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">331 (31.1%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">519 (38.1%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">334 (33.1%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">369 (39.9%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">484 (33.5%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 3</td>
<td rowspan="1" colspan="1">254 (19.3%)<a href="#ehad347-tblfn5" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">141 (13.3%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">217 (15.9%)</td>
<td rowspan="1" colspan="1">178 (17.6%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">167 (18.1%)</td>
<td rowspan="1" colspan="1">228 (15.8%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Missing</td>
<td rowspan="1" colspan="1">13</td>
<td rowspan="1" colspan="1">24</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">19</td>
<td rowspan="1" colspan="1">18</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">10</td>
<td rowspan="1" colspan="1">27</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">NT-proBNP (ng/L)</td>
<td rowspan="1" colspan="1">3369 (1886–5912)</td>
<td rowspan="1" colspan="1">2391 (1285–4540)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">2999 (1591–5274)</td>
<td rowspan="1" colspan="1">2850 (1479–5381)</td>
<td rowspan="1" colspan="1">.095</td>
<td rowspan="1" colspan="1">3136 (1806–5420)</td>
<td rowspan="1" colspan="1">2732 (1433–5248)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">eGFR (mL/min/1.73 m²)</td>
<td rowspan="1" colspan="1">56 (45–69)</td>
<td rowspan="1" colspan="1">62 (48–75)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">58 (46–70)</td>
<td rowspan="1" colspan="1">60 (46–73)</td>
<td rowspan="1" colspan="1">.139</td>
<td rowspan="1" colspan="1">55 (45–68)</td>
<td rowspan="1" colspan="1">60 (47–74)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">6-Min walk test (meters)</td>
<td rowspan="1" colspan="1">343 (230–422)</td>
<td rowspan="1" colspan="1">358 (268–442)</td>
<td rowspan="1" colspan="1">.001</td>
<td rowspan="1" colspan="1">349 (242–428)</td>
<td rowspan="1" colspan="1">335 (253–433)</td>
<td rowspan="1" colspan="1">.985</td>
<td rowspan="1" colspan="1">336 (230–424)</td>
<td rowspan="1" colspan="1">358 (266–437)</td>
<td rowspan="1" colspan="1">.004</td>
</tr>
<tr>
<td rowspan="1" colspan="1">6-Min walk test (% predicted)</td>
<td rowspan="1" colspan="1">68.0 ± 26.6</td>
<td rowspan="1" colspan="1">75.7 ± 25.7</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">71.3 ± 26.4</td>
<td rowspan="1" colspan="1">71.0 ± 26.6</td>
<td rowspan="1" colspan="1">.853</td>
<td rowspan="1" colspan="1">67.9 ± 26.4</td>
<td rowspan="1" colspan="1">74.0 ± 26.3</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td>
<td rowspan="1" colspan="1">123.7 ± 20.2</td>
<td rowspan="1" colspan="1">127.0 ± 22.9</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">124.8 ± 20.8</td>
<td rowspan="1" colspan="1">125.6 ± 22.3</td>
<td rowspan="1" colspan="1">.028</td>
<td rowspan="1" colspan="1">121.8 ± 19.2</td>
<td rowspan="1" colspan="1">127.3 ± 22.6</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td>
<td rowspan="1" colspan="1">74.0 ± 12.5</td>
<td rowspan="1" colspan="1">74.9 ± 13.0</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">74.0 ± 13.3</td>
<td rowspan="1" colspan="1">75.0 ± 13.5</td>
<td rowspan="1" colspan="1">.004</td>
<td rowspan="1" colspan="1">72.8 ± 11.5</td>
<td rowspan="1" colspan="1">75.5 ± 14.1</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Heart rate (b.p.m.)</td>
<td rowspan="1" colspan="1">71.2 ± 14.0</td>
<td rowspan="1" colspan="1">73.5 ± 13.1</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">71.9 ± 13.5</td>
<td rowspan="1" colspan="1">72.7 ± 13.9</td>
<td rowspan="1" colspan="1">.230</td>
<td rowspan="1" colspan="1">72.0 ± 14.1</td>
<td rowspan="1" colspan="1">72.4 ± 13.4</td>
<td rowspan="1" colspan="1">.471</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Echocardiographic parameters</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">IVSd (mm)</td>
<td rowspan="1" colspan="1">17.00 ± 2.4</td>
<td rowspan="1" colspan="1">16.9 ± 2.5</td>
<td rowspan="1" colspan="1">.672</td>
<td rowspan="1" colspan="1">17.0 ± 2.5</td>
<td rowspan="1" colspan="1">16.8 ± 2.4</td>
<td rowspan="1" colspan="1">.051</td>
<td rowspan="1" colspan="1">17.1 ± 2.4</td>
<td rowspan="1" colspan="1">16.8 ± 2.5</td>
<td rowspan="1" colspan="1">.015</td>
</tr>
<tr>
<td rowspan="1" colspan="1">PWTd (mm)</td>
<td rowspan="1" colspan="1">16.4 ± 2.5</td>
<td rowspan="1" colspan="1">16.3 ± 2.6</td>
<td rowspan="1" colspan="1">.761</td>
<td rowspan="1" colspan="1">16.4 ± 2.5</td>
<td rowspan="1" colspan="1">16.3 ± 2.5</td>
<td rowspan="1" colspan="1">.412</td>
<td rowspan="1" colspan="1">16.5 ± 2.5</td>
<td rowspan="1" colspan="1">16.3 ± 2.5</td>
<td rowspan="1" colspan="1">.014</td>
</tr>
<tr>
<td rowspan="1" colspan="1">MWT (mm)</td>
<td rowspan="1" colspan="1">17.1 ± 2.4</td>
<td rowspan="1" colspan="1">17.1 ± 2.5</td>
<td rowspan="1" colspan="1">.677</td>
<td rowspan="1" colspan="1">17.2 ± 2.4</td>
<td rowspan="1" colspan="1">17.0 ± 2.4</td>
<td rowspan="1" colspan="1">.061</td>
<td rowspan="1" colspan="1">17.3 ± 2.3</td>
<td rowspan="1" colspan="1">17.0 ± 2.5</td>
<td rowspan="1" colspan="1">.020</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Left atrial area (cm<sup>2</sup>)</td>
<td rowspan="1" colspan="1">26.7 ± 5.4</td>
<td rowspan="1" colspan="1">25.6 ± 6.4</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">26.54 ± 5.6</td>
<td rowspan="1" colspan="1">25.78 ± 5.4</td>
<td rowspan="1" colspan="1">.008</td>
<td rowspan="1" colspan="1">26.5 ± 5.4</td>
<td rowspan="1" colspan="1">26.0 ± 5.7</td>
<td rowspan="1" colspan="1">.113</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Right atrial area (cm<sup>2</sup>)</td>
<td rowspan="1" colspan="1">25.1 ± 6.4</td>
<td rowspan="1" colspan="1">23.5 ± 6.4</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">24.9 ± 6.6</td>
<td rowspan="1" colspan="1">23.8 ± 6.6</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">25.1 ± 5.4</td>
<td rowspan="1" colspan="1">24.0 ± 6.4</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Stroke volume (mL)</td>
<td rowspan="1" colspan="1">36.6 ± 13.9</td>
<td rowspan="1" colspan="1">38.3 ± 14.0</td>
<td rowspan="1" colspan="1">.023</td>
<td rowspan="1" colspan="1">37.7 ± 14.5</td>
<td rowspan="1" colspan="1">36.6 ± 13.0</td>
<td rowspan="1" colspan="1">.126</td>
<td rowspan="1" colspan="1">35.9 ± 13.0</td>
<td rowspan="1" colspan="1">38.5 ± 14.6</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">LVEF (%)</td>
<td rowspan="1" colspan="1">47.1 ± 10.7</td>
<td rowspan="1" colspan="1">49.5 ± 10.4</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">47.7 ± 10.6</td>
<td rowspan="1" colspan="1">48.8 ± 10.7</td>
<td rowspan="1" colspan="1">.013</td>
<td rowspan="1" colspan="1">46.4 ± 10.6</td>
<td rowspan="1" colspan="1">49.3 ± 10.5</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">LVEF ≤40%</td>
<td rowspan="1" colspan="1">342 (26.0%)</td>
<td rowspan="1" colspan="1">189 (17.9%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">321 (23.6%)</td>
<td rowspan="1" colspan="1">210 (20.8%)</td>
<td rowspan="1" colspan="1">.112</td>
<td rowspan="1" colspan="1">252 (27.2%)</td>
<td rowspan="1" colspan="1">279 (19.3%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Longitudinal strain (%)</td>
<td rowspan="1" colspan="1">−10.6 ± 3.5</td>
<td rowspan="1" colspan="1">−11.1 ± 3.8</td>
<td rowspan="1" colspan="1">&lt;.001</td>
<td rowspan="1" colspan="1">−10.6 ± 3.5</td>
<td rowspan="1" colspan="1">−11.0 ± 3.7</td>
<td rowspan="1" colspan="1">.014</td>
<td rowspan="1" colspan="1">−10.2 ± 3.3</td>
<td rowspan="1" colspan="1">−11.2 ± 3.8</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">TAPSE (mm)</td>
<td rowspan="1" colspan="1">14.7 ± 4.8</td>
<td rowspan="1" colspan="1">15.5 ± 5.0</td>
<td rowspan="1" colspan="1">.002</td>
<td rowspan="1" colspan="1">15.0 ± 4.7</td>
<td rowspan="1" colspan="1">15.2 ± 5.2</td>
<td rowspan="1" colspan="1">.342</td>
<td rowspan="1" colspan="1">14.6 ± 4.8</td>
<td rowspan="1" colspan="1">15.5 ± 5.0</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">E/e′</td>
<td rowspan="1" colspan="1">16.7 ± 6.4</td>
<td rowspan="1" colspan="1">16.7 ± 6.5</td>
<td rowspan="1" colspan="1">.567</td>
<td rowspan="1" colspan="1">16.9 ± 6.2</td>
<td rowspan="1" colspan="1">16.7 ± 6.7</td>
<td rowspan="1" colspan="1">.640</td>
<td rowspan="1" colspan="1">17.2 ± 6.5</td>
<td rowspan="1" colspan="1">16.3 ± 6.3</td>
<td rowspan="1" colspan="1">.036</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/ehad347-T2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="ehad347-tblfn4"><p>BSA, body surface area; AF, atrial fibrillation; IHD, ischaemic heart disease; TIA, transient ischaemic attack; CKD, chronic kidney disease; PPM, permanent pacemaker; ICD, implantable cardioverter defibrillator; CRT-D, cardiac resynchronization therapy defibrillator; CRT-P, cardiac resynchronization therapy pacemaker; NYHA, New York Heart Association; NAC, National Amyloidosis Centre; NT-proBNP, N-terminal pro B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; IVSd, interventricular septum in diastole; PWTd, posterior wall thickness in diastole; MWT, maximal wall thickness; LVEF, left ventricular ejection fraction.</p></div>
<div class="fn" id="ehad347-tblfn5"><p>
<em>P</em> &lt; .05.</p></div>
</div></section></section><section id="ehad347-s2.1.4"><h4 class="pmc_sec_title">Combination heart failure therapy</h4>
<p>A total of 417 (17.6%) patients were treated with all three classes of HF medications (beta-blocker, ACEi/ARB, and MRA) at diagnosis, 804 (33.9%) were treated with a combination of two classes of HF medications, 741 (31.3%) were treated with one of the three classes of HF medications, and 409 (17.2%) were not treated with any prognostic HF medications. The most frequent combination of two HF medications was a beta-blocker and ACEi/ARB in 454 (56.5%) patients, followed by a beta-blocker and MRA in 180 (22.4%) patients, and an ACEi/ARB and MRA in 170 (21.1%) patients. Those treated with more HF medications had a higher prevalence of IHD, diabetes mellitus, and atrial fibrillation. They had more severe HF, with a worse functional status, as evidenced by NYHA class and 6MWT, and a higher NAC disease stage, and a higher proportion of patients having chronic kidney disease stages 3–5. Patients treated with more HF medications had a larger left ventricular wall thickness, larger bi-atrial size, and worse biventricular systolic function (reflected in a lower TAPSE, LVEF, and worse longitudinal strain), and there was a greater use of HF medications in patients with a LVEF ≤40%(<em><a href="#ehad347-T3" class="usa-link">Table 3</a></em>).</p>
<section class="tw xbox font-sm" id="ehad347-T3"><h5 class="obj_head">Table 3.</h5>
<div class="caption p"><p>Baseline characteristics and echocardiographic parameters for the overall population, separated by the number of heart failure medications patients were treated with</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col valign="top" align="left" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1">Baseline characteristics</th>
<th align="center" rowspan="1" colspan="1">Not treated with HF medications (<em>n</em> = 409, 17.2%)</th>
<th align="center" rowspan="1" colspan="1">Treated with one HF medication (<em>n</em> = 741, 31.3%)</th>
<th align="center" rowspan="1" colspan="1">Treated with two HF medications (<em>n</em> = 804, 33.9%)</th>
<th align="center" rowspan="1" colspan="1">Treated with three HF medications (<em>n</em> = 417, 17.6%)</th>
<th align="center" rowspan="1" colspan="1">
<em>P</em>-value</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">Age</td>
<td rowspan="1" colspan="1">76.8 ± 9.0<a href="#ehad347-tblfn7" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="1" colspan="1">78.5 ± 6.9<a href="#ehad347-tblfn11" class="usa-link"><sup>*****</sup></a>
</td>
<td rowspan="1" colspan="1">77.6 ± 6.6<a href="#ehad347-tblfn12" class="usa-link"><sup>******</sup></a>
</td>
<td rowspan="1" colspan="1">76.1 ± 6.9</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Sex (male)</td>
<td rowspan="1" colspan="1">359 (87.8%)</td>
<td rowspan="1" colspan="1">653 (88.1%)</td>
<td rowspan="1" colspan="1">727 (90.4%)</td>
<td rowspan="1" colspan="1">371 (89.0%)</td>
<td rowspan="1" colspan="1">.412</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Ethnicity</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Caucasian</td>
<td rowspan="1" colspan="1">336 (82.2%)<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">615 (83.0%)<a href="#ehad347-tblfn11" class="usa-link"><sup>*****</sup></a>
</td>
<td rowspan="1" colspan="1">647 (80.5%)<a href="#ehad347-tblfn12" class="usa-link"><sup>******</sup></a>
</td>
<td rowspan="1" colspan="1">295 (70.7%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Afro-Caribbean</td>
<td rowspan="1" colspan="1">66 (16.1%)<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">113 (15.2%)<a href="#ehad347-tblfn11" class="usa-link"><sup>*****</sup></a>
</td>
<td rowspan="1" colspan="1">146 (18.2%)<a href="#ehad347-tblfn12" class="usa-link"><sup>******</sup></a>
</td>
<td rowspan="1" colspan="1">119 (28.5%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Asian</td>
<td rowspan="1" colspan="1">3 (0.7%)</td>
<td rowspan="1" colspan="1">10 (1.3%)</td>
<td rowspan="1" colspan="1">8 (1.0%)</td>
<td rowspan="1" colspan="1">1 (0.2%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Other</td>
<td rowspan="1" colspan="1">4 (1.0%)</td>
<td rowspan="1" colspan="1">3 (0.4%)</td>
<td rowspan="1" colspan="1">3 (0.4%)</td>
<td rowspan="1" colspan="1">2 (0.5%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">wtATTR</td>
<td rowspan="1" colspan="1">298 (72.9%)<a href="#ehad347-tblfn7" class="usa-link"><sup>*</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">607 (81.9%)<a href="#ehad347-tblfn11" class="usa-link"><sup>*****</sup></a>
</td>
<td rowspan="1" colspan="1">638 (79.4%)<a href="#ehad347-tblfn12" class="usa-link"><sup>******</sup></a>
</td>
<td rowspan="1" colspan="1">297 (71.2%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">hATTR</td>
<td rowspan="1" colspan="1">111 (27.1%)<a href="#ehad347-tblfn7" class="usa-link"><sup>*</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">134 (18.1%)<a href="#ehad347-tblfn11" class="usa-link"><sup>*****</sup></a>
</td>
<td rowspan="1" colspan="1">166 (20.6%)<a href="#ehad347-tblfn12" class="usa-link"><sup>******</sup></a>
</td>
<td rowspan="1" colspan="1">120 (28.8%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">AF/flutter</td>
<td rowspan="1" colspan="1">145 (35.5%)<a href="#ehad347-tblfn7" class="usa-link"><sup>*</sup></a>,<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">389 (52.5%)</td>
<td rowspan="1" colspan="1">458 (57.0%)</td>
<td rowspan="1" colspan="1">231 (55.4%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">IHD</td>
<td rowspan="1" colspan="1">54 (13.2%)<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">142 (19.2%)</td>
<td rowspan="1" colspan="1">183 (22.8%)</td>
<td rowspan="1" colspan="1">97 (23.3%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Diabetes mellitus</td>
<td rowspan="1" colspan="1">41 (10.0%)<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">104 (14.0%)<a href="#ehad347-tblfn11" class="usa-link"><sup>*****</sup></a>
</td>
<td rowspan="1" colspan="1">133 (16.5%)</td>
<td rowspan="1" colspan="1">96 (15.8%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Hypertension</td>
<td rowspan="1" colspan="1">92 (22.5%)<a href="#ehad347-tblfn7" class="usa-link"><sup>*</sup></a>,<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">276 (37.2%)</td>
<td rowspan="1" colspan="1">293 (36.4%)</td>
<td rowspan="1" colspan="1">167 (40.0%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Stroke/TIA</td>
<td rowspan="1" colspan="1">50 (12.2%)</td>
<td rowspan="1" colspan="1">78 (10.5%)</td>
<td rowspan="1" colspan="1">91 (11.3%)</td>
<td rowspan="1" colspan="1">39 (9.4%)</td>
<td rowspan="1" colspan="1">.568</td>
</tr>
<tr>
<td rowspan="1" colspan="1">CKD stages 3–5</td>
<td rowspan="1" colspan="1">151 (36.9%)<a href="#ehad347-tblfn7" class="usa-link"><sup>*</sup></a>,<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">394 (53.2%)<a href="#ehad347-tblfn11" class="usa-link"><sup>*****</sup></a>
</td>
<td rowspan="1" colspan="1">479 (59.6%)</td>
<td rowspan="1" colspan="1">264 (63.3%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Cardiac devices</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">PPM</td>
<td rowspan="1" colspan="1">30 (7.4%)</td>
<td rowspan="1" colspan="1">55 (7.4%)</td>
<td rowspan="1" colspan="1">91 (11.3%)</td>
<td rowspan="1" colspan="1">378 (9.1%)</td>
<td rowspan="1" colspan="1">.031</td>
</tr>
<tr>
<td rowspan="1" colspan="1">ICD</td>
<td rowspan="1" colspan="1">6 (1.5%)</td>
<td rowspan="1" colspan="1">11 (1.5%)</td>
<td rowspan="1" colspan="1">16 (2.0%)</td>
<td rowspan="1" colspan="1">13 (3.1%)</td>
<td rowspan="1" colspan="1">.227</td>
</tr>
<tr>
<td rowspan="1" colspan="1">CRT-D</td>
<td rowspan="1" colspan="1">1 (0.2%)</td>
<td rowspan="1" colspan="1">6 (0.8%)</td>
<td rowspan="1" colspan="1">9 (1.1%)</td>
<td rowspan="1" colspan="1">7 (1.7%)</td>
<td rowspan="1" colspan="1">.187</td>
</tr>
<tr>
<td rowspan="1" colspan="1">CRT-P</td>
<td rowspan="1" colspan="1">1 (0.2%)</td>
<td rowspan="1" colspan="1">13 (1.8%)</td>
<td rowspan="1" colspan="1">17 (2.1%)</td>
<td rowspan="1" colspan="1">6 (1.4%)</td>
<td rowspan="1" colspan="1">.092</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Heart failure severity</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">NYHA class</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 1</td>
<td rowspan="1" colspan="1">105 (25.7%)<a href="#ehad347-tblfn7" class="usa-link"><sup>*</sup></a>,<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">92 (12.4%)<a href="#ehad347-tblfn11" class="usa-link"><sup>*****</sup></a>
</td>
<td rowspan="1" colspan="1">87 (10.8%)</td>
<td rowspan="1" colspan="1">33 (7.9%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 2</td>
<td rowspan="1" colspan="1">251 (61.4%)</td>
<td rowspan="1" colspan="1">412 (55.6%)</td>
<td rowspan="1" colspan="1">479 (59.6%)<a href="#ehad347-tblfn12" class="usa-link"><sup>******</sup></a>
</td>
<td rowspan="1" colspan="1">245 (58.8%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 3</td>
<td rowspan="1" colspan="1">50 (12.2%)<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">120 (16.2%)<a href="#ehad347-tblfn11" class="usa-link"><sup>*****</sup></a>
</td>
<td rowspan="1" colspan="1">135 (16.8%)<a href="#ehad347-tblfn12" class="usa-link"><sup>******</sup></a>
</td>
<td rowspan="1" colspan="1">130 (31.2%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 4</td>
<td rowspan="1" colspan="1">3 (0.7%)</td>
<td rowspan="1" colspan="1">9 (1.2%)</td>
<td rowspan="1" colspan="1">10 (1.2%)</td>
<td rowspan="1" colspan="1">8 (1.9%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Missing</td>
<td rowspan="1" colspan="1">0</td>
<td rowspan="1" colspan="1">108</td>
<td rowspan="1" colspan="1">93</td>
<td rowspan="1" colspan="1">1</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">NAC stage</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 1</td>
<td rowspan="1" colspan="1">214 (52.3%)<a href="#ehad347-tblfn7" class="usa-link"><sup>*</sup></a>,<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">346 (46.7%)</td>
<td rowspan="1" colspan="1">333 (41.4%)</td>
<td rowspan="1" colspan="1">166 (39.8%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 2</td>
<td rowspan="1" colspan="1">133 (32.5%)<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">247 (33.3%)<a href="#ehad347-tblfn11" class="usa-link"><sup>*****</sup></a>
</td>
<td rowspan="1" colspan="1">316 (39.3%)</td>
<td rowspan="1" colspan="1">177 (42.4%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> 3</td>
<td rowspan="1" colspan="1">44 (10.8%)<a href="#ehad347-tblfn7" class="usa-link"><sup>*</sup></a>,<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>
</td>
<td rowspan="1" colspan="1">135 (18.2%)</td>
<td rowspan="1" colspan="1">145 (18.0%)</td>
<td rowspan="1" colspan="1">71 (17.0%)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Missing</td>
<td rowspan="1" colspan="1">18</td>
<td rowspan="1" colspan="1">13</td>
<td rowspan="1" colspan="1">10</td>
<td rowspan="1" colspan="1">3</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">NT-proBNP (ng/L)</td>
<td rowspan="1" colspan="1">2142 (1038–4224)<a href="#ehad347-tblfn7" class="usa-link"><sup>*</sup></a>,<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">2899 (1517–5259)<a href="#ehad347-tblfn10" class="usa-link"><sup>****</sup></a>
</td>
<td rowspan="1" colspan="1">3254 (1705–5785)</td>
<td rowspan="1" colspan="1">3201 (1958–5454)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">eGFR (mL/min/1.73 m²)</td>
<td rowspan="1" colspan="1">66 (52–79)<a href="#ehad347-tblfn7" class="usa-link"><sup>*</sup></a>,<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">59 (45–71)</td>
<td rowspan="1" colspan="1">56 (45–70)</td>
<td rowspan="1" colspan="1">55 (46–66)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">6-Min walk test (meters)</td>
<td rowspan="1" colspan="1">368 (276–447)<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">350 (264–437)</td>
<td rowspan="1" colspan="1">345 (241–431)</td>
<td rowspan="1" colspan="1">332 (221–414)</td>
<td rowspan="1" colspan="1">.015</td>
</tr>
<tr>
<td rowspan="1" colspan="1">6-Min walk test (% predicted)</td>
<td rowspan="1" colspan="1">75.8 ± 26.8<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">74.0 ± 26.0<a href="#ehad347-tblfn11" class="usa-link"><sup>*****</sup></a>
</td>
<td rowspan="1" colspan="1">70.7 ± 25.9</td>
<td rowspan="1" colspan="1">65.4 ± 27.0</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td>
<td rowspan="1" colspan="1">127.6 ± 25.6<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">128.0 ± 20.5<a href="#ehad347-tblfn10" class="usa-link"><sup>****</sup></a>,<a href="#ehad347-tblfn11" class="usa-link"><sup>*****</sup></a>
</td>
<td rowspan="1" colspan="1">123.2 ± 20.9</td>
<td rowspan="1" colspan="1">121.9 ± 18.8</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td>
<td rowspan="1" colspan="1">75.3 ± 14.6<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">76.0 ± 12.5<a href="#ehad347-tblfn10" class="usa-link"><sup>****</sup></a>,<a href="#ehad347-tblfn11" class="usa-link"><sup>*****</sup></a>
</td>
<td rowspan="1" colspan="1">73.6 ± 12.6</td>
<td rowspan="1" colspan="1">72.5 ± 11.4</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Heart rate (b.p.m.)</td>
<td rowspan="1" colspan="1">73.8 ± 13.0<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>
</td>
<td rowspan="1" colspan="1">72.7 ± 13.3</td>
<td rowspan="1" colspan="1">71.5 ± 14.2</td>
<td rowspan="1" colspan="1">71.3 ± 13.6</td>
<td rowspan="1" colspan="1">.008</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Echocardiographic parameters</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">IVSd (mm)</td>
<td rowspan="1" colspan="1">16.6 ± 2.5<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>
</td>
<td rowspan="1" colspan="1">16.9 ± 2.5</td>
<td rowspan="1" colspan="1">17.1 ± 2.5</td>
<td rowspan="1" colspan="1">16.9 ± 2.2</td>
<td rowspan="1" colspan="1">.011</td>
</tr>
<tr>
<td rowspan="1" colspan="1">PWTd (mm)</td>
<td rowspan="1" colspan="1">16.0 ± 2.6<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>
</td>
<td rowspan="1" colspan="1">16.4 ± 2.4</td>
<td rowspan="1" colspan="1">16.5 ± 2.5</td>
<td rowspan="1" colspan="1">16.2 ± 2.6</td>
<td rowspan="1" colspan="1">.007</td>
</tr>
<tr>
<td rowspan="1" colspan="1">MWT (mm)</td>
<td rowspan="1" colspan="1">16.8 ± 2.5<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>
</td>
<td rowspan="1" colspan="1">17.1 ± 2.4</td>
<td rowspan="1" colspan="1">17.3 ± 2.5</td>
<td rowspan="1" colspan="1">17.1 ± 2.2</td>
<td rowspan="1" colspan="1">.008</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Left atrial area (cm<sup>2</sup>)</td>
<td rowspan="1" colspan="1">25.1 ± 5.5<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">25.9 ± 5.7</td>
<td rowspan="1" colspan="1">26.6 ± 5.4</td>
<td rowspan="1" colspan="1">26.8 ± 5.4</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Right atrial area (cm<sup>2</sup>)</td>
<td rowspan="1" colspan="1">22.6 ± 6.2<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">23.7 ± 6.5<a href="#ehad347-tblfn10" class="usa-link"><sup>****</sup></a>,<a href="#ehad347-tblfn11" class="usa-link"><sup>*****</sup></a>
</td>
<td rowspan="1" colspan="1">25.3 ± 6.1</td>
<td rowspan="1" colspan="1">25.4 ± 6.7</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Stroke volume (mL)</td>
<td rowspan="1" colspan="1">38.4 ± 13.8</td>
<td rowspan="1" colspan="1">38.2 ± 14.2</td>
<td rowspan="1" colspan="1">36.8 ± 13.8</td>
<td rowspan="1" colspan="1">36.3 ± 13.8</td>
<td rowspan="1" colspan="1">.158</td>
</tr>
<tr>
<td rowspan="1" colspan="1">LVEF (%)</td>
<td rowspan="1" colspan="1">50.4 ± 10.2<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">49.0 ± 10.5<a href="#ehad347-tblfn11" class="usa-link"><sup>*****</sup></a>
</td>
<td rowspan="1" colspan="1">48.0 ± 10.8<a href="#ehad347-tblfn12" class="usa-link"><sup>******</sup></a>
</td>
<td rowspan="1" colspan="1">45.1 ± 10.2</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">LVEF ≤40%</td>
<td rowspan="1" colspan="1">62 (15.2%)<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">155 (20.9%)</td>
<td rowspan="1" colspan="1">182 (22.6%)<a href="#ehad347-tblfn12" class="usa-link"><sup>******</sup></a>
</td>
<td rowspan="1" colspan="1">132 (31.7%)</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Longitudinal strain (%)</td>
<td rowspan="1" colspan="1">−11.6 ± 4.0<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">−11.2 ± 3.7<a href="#ehad347-tblfn10" class="usa-link"><sup>****</sup></a>
</td>
<td rowspan="1" colspan="1">−10.4 ± 3.4</td>
<td rowspan="1" colspan="1">−10.1 ± 3.3</td>
<td rowspan="1" colspan="1">&lt;.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">TAPSE (mm)</td>
<td rowspan="1" colspan="1">15.9 ± 5.1<a href="#ehad347-tblfn8" class="usa-link"><sup>**</sup></a>,<a href="#ehad347-tblfn9" class="usa-link"><sup>***</sup></a>
</td>
<td rowspan="1" colspan="1">15.4 ± 5.0</td>
<td rowspan="1" colspan="1">14.7 ± 5.0</td>
<td rowspan="1" colspan="1">14.6 ± 4.4</td>
<td rowspan="1" colspan="1">.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">E/e′</td>
<td rowspan="1" colspan="1">16.5 ± 6.9</td>
<td rowspan="1" colspan="1">16.8 ± 6.4</td>
<td rowspan="1" colspan="1">16.8 ± 6.0</td>
<td rowspan="1" colspan="1">17.1 ± 6.6</td>
<td rowspan="1" colspan="1">.707</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/ehad347-T3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="ehad347-tblfn6"><p>HF, heart failure; AF, atrial fibrillation; IHD, ischaemic heart disease; TIA, transient ischaemic attack; CKD, chronic kidney disease; PPM, permanent pacemaker; ICD, implantable cardioverter defibrillator; CRT-D, cardiac resynchronization therapy defibrillator; CRT-P, cardiac resynchronization therapy pacemaker; NYHA, New York Heart Association; NAC, National Amyloidosis Centre; NT-proBNP, N-terminal pro B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; IVSd, interventricular septum in diastole; PWTd, posterior wall thickness in diastole; MWT, maximal wall thickness; LVEF, left ventricular ejection fraction.</p></div>
<div class="fn" id="ehad347-tblfn7"><p>
<em>P</em> &lt; .05 for no HF medications vs. one HF medication.</p></div>
<div class="fn" id="ehad347-tblfn8"><p>
<em>P</em> &lt; .05 for no HF medications vs. two HF medications.</p></div>
<div class="fn" id="ehad347-tblfn9"><p>
<em>P</em> &lt; .05 for no HF medications vs. three HF medications.</p></div>
<div class="fn" id="ehad347-tblfn10"><p>
<em>P</em> &lt; .05 for one HF medication vs. two HF medications.</p></div>
<div class="fn" id="ehad347-tblfn11"><p>
<em>P</em> &lt; .05 for one HF medication vs. three HF medications.</p></div>
<div class="fn" id="ehad347-tblfn12"><p>
<em>P</em> &lt; .05 for two HF medications vs. three HF medications.</p></div>
</div></section></section></section><section id="ehad347-s2.2"><h3 class="pmc_sec_title">Doses of heart failure medications and discontinuation rates</h3>
<section id="ehad347-s2.2.1"><h4 class="pmc_sec_title">Beta-blockers</h4>
<p>Of the 1313 patients treated with beta-blockers, over half were treated with ≤25% of the target dose for HF (<em>n</em> = 829, 63.1%).<sup><a href="#ehad347-B19" class="usa-link" aria-describedby="ehad347-B19">19</a></sup> The most commonly prescribed beta-blocker was bisoprolol (<em>n</em> = 1164, 88.7%), with the majority of patients treated with ≤2.5 mg per day (<em>n</em> = 721, 61.9%). Only 75 (5.7%) patients had the target beta-blocker dose prescribed, most of which had atrial fibrillation (<em>n</em> = 58, 77.3%). The overwhelming majority of the study population (<em>n</em> = 1266, 96.4%) and all patients with a LVEF ≤40% (<em>n</em> = 342, 100.0%) were treated with beta-blockers approved for HF with reduced ejection fraction. During follow-up 285 (21.7%) patients had their beta-blocker discontinued [median duration to discontinuation: 14.1 (6.8–28.9) months], and 117 (8.9%) had their beta-blocker dose reduced [median duration to reduction: 15.7 (7.4–34.5) months]. Patients who discontinued beta-blocker treatment had a lower blood pressure and heart rate than those who continued treatment. Only 63 (4.8%) patients had their beta-blocker dose increased, of which only 8 patients eventually had the target dose prescribed. During follow-up, 55 patients were initiated on beta-blockers, and the majority were treated with ≤25% of the target dose (<em>n</em> = 44, 80.0%), of which 4 (7.2%) had their beta-blocker subsequently discontinued.</p></section><section id="ehad347-s2.2.2"><h4 class="pmc_sec_title">Renin-angiotensin system blockers</h4>
<p>Of the 1362 patients treated with ACEi/ARBs, over half were treated with ≤37.5% of the target dose (<em>n</em> = 728, 53.5%).<sup><a href="#ehad347-B19" class="usa-link" aria-describedby="ehad347-B19">19</a></sup> The most commonly prescribed ACEi/ARB was ramipril (<em>n</em> = 701, 51.4%), with the majority of patients treated with ≤2.5 mg per day (<em>n</em> = 354, 50.5%). Only 158 (11.6%) patients were treated with the target ACEi/ARB dose. During follow-up 448 (32.9%) patients had their ACEi/ARB discontinued [median duration to discontinuation: 14.4 (6.9–26.8) months], and 77 (5.7%) had their ACEi/ARB dose reduced [median duration to reduction: 14.2 (7.4–26.6) months]. Patients who discontinued ACEi/ARB treatment had a lower blood pressure than those who continued treatment (see <a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Table S2</a></em>). Only 35 (2.6%) patients had their ACEi/ARB dose increased, of which only 3 patients were treated with the target dose. During follow-up, 41 patients were initiated on ACEi/ARBs, and the majority were treated with ≤37.5% of the target dose (<em>n</em> = 26, 63.4%) of which 8 (19.5%) had their ACEi/ARB subsequently discontinued.</p></section><section id="ehad347-s2.2.3"><h4 class="pmc_sec_title">Mineralocorticoid receptor antagonists</h4>
<p>Of the 925 patients treated with MRAs, 742 (80.2%) were treated with spironolactone, and 183 (19.3%) were treated with eplerenone. The most commonly prescribed dose of both drugs was 25 mg (<em>n</em> = 657, 71.0%), followed by 50 mg (<em>n</em> = 79, 8.5%). During follow-up 69 (7.5%) patients had their MRAs discontinued [median duration to discontinuation: 12.5 (7.9–24.9) months], and 31 (3.4%) had their MRA dose reduced [median duration to reduction: 14.1 (7.9–24.9) months]. Only 77 (8.3%) patients had the dose of their MRA increased, of which 53 were prescribed with 50 mg. During follow-up, 158 patients were initiated on MRAs, and the majority were treated with ≥25 mg (<em>n</em> = 129, 81.6%), of which only 5 (3.2%) had their MRA subsequently discontinued.</p></section></section><section id="ehad347-s2.3"><h3 class="pmc_sec_title">Association between heart failure medication classes and survival</h3>
<p>In the overall population, median follow-up was 27.8 months (IQR: 10.6–51.3), and the death rate was 14.9 deaths per 100 patient-years (95% CI 13.9–15.9). There were 1274 patients classed as being treated with beta-blockers for the survival analysis, and the death rate was 14.8 deaths per 100 patient-years (95% CI 13.5–16.2). There were 1306 patients classed as being treated with ACEi/ARBs for the survival analysis, and the death rate was 15.0 deaths per 100 patient-years (95% CI 13.8–16.4). There were 915 patients classed as being treated with MRAs for the survival analysis, and the death rate was 14.6 deaths per 100 patient-years (95% CI 13.1–16.1).</p>
<section id="ehad347-s2.3.1"><h4 class="pmc_sec_title">Multivariable Cox regression model</h4>
<p>In a multivariable Cox regression analysis with covariates age, sex, IHD, diabetes mellitus, hypertension, atrial fibrillation, NAC disease stage, wild-type or hereditary ATTR-CA, IVSd, longitudinal strain, beta-blocker, ACEi/ARB, and MRA, only 4 covariates (age, hATTR-CA, higher NAC disease stage, and worse longitudinal strain) were associated with a higher risk of mortality; and only one treatment [MRA: HR 0.82 (95% CI 0.71–0.94), <em>P</em> = .004] was convincingly associated with a lower risk of mortality (see <a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Table S3</a></em>).</p></section><section id="ehad347-s2.3.2"><h4 class="pmc_sec_title">Propensity score-matched analyses</h4>
<p>To minimize the potential selection bias inherent with the baseline treatment of HF medications we also performed PS-matched cohort analyses to assess the association between treatment with each HF medication and survival. Missing data were imputed for NAC stage in 37 patients, IVSd in 115 patients, and longitudinal strain in 296 patients. The remaining variables did not have any missing data. The PS-matched cohort constructed to assess the association between treatment with beta-blockers and risk of mortality comprised of 1756 patients (878 treated with beta-blockers vs. 878 not treated with beta-blockers) and did not provide convincing evidence for a difference in the risk of mortality between the two groups [HR 0.89 (95% CI 0.77–1.04), <em>P</em> = .149], although the 95% CI of the estimate was wide and did not exclude clinically important effects (see <a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Table S4</a></em>). A second PS-matched cohort was constructed to assess the association between treatment with beta-blockers and risk of mortality in patients with a LVEF ≤40%. This comprised of 338 patients (169 treated with beta-blockers vs. 169 not treated with beta-blockers), and demonstrated a 39% lower risk of mortality in patients treated with beta-blockers [HR 0.61 (95% CI 0.45–0.83), <em>P</em> = .002] (see <a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Table S5</a></em>). These findings were confirmed with sensitivity analysis, utilizing an ‘intention to treat’ approach [HR 0.58 (95% CI 0.42–0.81), <em>P</em> = .001], and whereby patients were no longer censored for the start date of clinical trials and disease modifying therapy [HR 0.63 (95% CI 0.47–0.85), <em>P</em> = .003], and where beta-blocker treatment was analysed as a time-varying exposure [HR 0.51 (95% CI 0.37–0.71), <em>P</em> &lt; .001]. Following exclusion of patients with coexistent IHD and their corresponding pairs, repeat analysis confirmed a lower risk of mortality in patients with a LVEF ≤40% treated with beta-blockers [HR 0.56 (95% CI 0.38–0.83), <em>P</em> = .003]. A third PS-matched cohort was constructed to assess the association between treatment with beta-blockers and risk of mortality in patients with a LVEF &gt;40%. This comprised of 1378 patients (689 treated with beta-blockers vs. 689 not treated with beta-blockers) and did not provide convincing evidence for a difference in the risk of mortality between the two groups [HR 1.00 (95% CI 0.84–1.20), <em>P</em> = .957], although the estimate was imprecise (<em><a href="#ehad347-F1" class="usa-link">Figure 1</a></em> and <a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Table S6</a></em>).</p>
<figure class="fig xbox font-sm" id="ehad347-F1"><h5 class="obj_head">Figure 1.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10424879_ehad347f1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ede/10424879/cd97f5a7742c/ehad347f1.jpg" loading="lazy" height="208" width="760" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/ehad347-F1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Kaplan–Meier curves comparing survival in patients treated with beta-blockers to patients not treated with beta-blockers followed by a Cox proportional hazards regression analysis: (<em>A</em>) treatment with beta-blockers vs. no treatment with beta-blockers in the overall population, (<em>B</em>) treatment with beta-blockers vs. no treatment with beta-blockers in patients with a LVEF ≤40%, (<em>C</em>) treatment with beta-blockers vs. no treatment with beta-blockers in patients with a LVEF &gt;40%</p></figcaption></figure><p>The PS-matched cohort constructed to assess the association between treatment with ACEi/ARBs and the risk of mortality comprised of 1782 patients (891 treated with ACEi/ARBs vs. 891 not treated with ACEi/ARBs) and did not provide convincing evidence for a difference in the risk of mortality between the two groups [HR 1.09 (95% CI 0.93–1.26), <em>P</em> = .283] (see <a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Table S7</a></em>). A second PS-matched analysis was constructed to assess the association between treatment with ACEi/ARBs and the risk of mortality in patients with a LVEF ≤40%. This comprised of 368 patients (184 treated with ACEi/ARBs vs. 184 not treated with ACEi/ARBs) and did not provide convincing evidence for a difference in the risk of mortality between the two groups [HR 1.01 (95% CI 0.76–1.33), <em>P</em> = .947], although the estimates were imprecise (<a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Table S8</a></em>). A third PS-matched analysis was constructed to assess the association between treatment with ACEi/ARBs and the risk of mortality in patients with a LVEF &gt;40%. This comprised of 1390 patients (695 treated with ACEi/ARBs vs. 695 not treated with ACEi/ARBs) and did not provide convincing evidence for a difference in the risk of mortality between the two groups [HR 1.13 (95% CI 0.94–1.35), <em>P</em> = .198] (<em><a href="#ehad347-F2" class="usa-link">Figure 2</a></em> and <a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Table S9</a></em>).</p>
<figure class="fig xbox font-sm" id="ehad347-F2"><h5 class="obj_head">Figure 2.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10424879_ehad347f2.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ede/10424879/4770db3f21b4/ehad347f2.jpg" loading="lazy" height="210" width="760" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/ehad347-F2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Kaplan–Meier curves comparing survival in patients treated with ACEi/ARBs to patients not treated with ACEi/ARBs followed by a Cox proportional hazards regression analysis: (<em>A</em>) treatment with ACEi/ARBs vs. no treatment with ACEi/ARBs in the overall population, (<em>B</em>) treatment with ACEi/ARBs vs. no treatment with ACEi/ARBs in patients with a LVEF ≤40%, (<em>C</em>) treatment with ACEi/ARBs vs. no treatment with ACEi/ARBs in patients with a LVEF &gt;40%</p></figcaption></figure><p>The PS-matched cohort constructed to assess the association between treatment with MRAs and the risk of mortality comprised of 1788 patients (894 patients treated with MRAs vs. 894 patients not treated with MRAs) and demonstrated that there was a 23% lower risk of mortality in patients treated with MRAs [HR 0.77 (95% CI 0.66–0.89), <em>P</em> &lt; .001] (see <a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Table S10</a></em>). These findings were confirmed with sensitivity analysis, utilizing an ‘intention to treat’ approach [HR 0.81 (95% CI 0.69–0.94), <em>P</em> = .006]; and whereby patients were no longer censored for the start date of clinical trials and disease modifying therapy [HR 0.78 (95% CI 0.67–0.90), <em>P</em> &lt; .001], and where MRA treatment was analysed as a time-varying exposure [HR 0.81 (95% CI 0.69–0.94), <em>P</em> = .004]. A second PS-matched analysis was constructed to assess the association between treatment with MRAs and the risk of mortality in patients with a LVEF ≤40%. This comprised of 416 patients (208 patients treated with MRAs vs. 208 patients not treated with MRAs) and did not provide convincing evidence for a difference in the risk of mortality between the two groups [HR 0.83 (95% CI 0.62–1.10), <em>P</em> = .192], although the 95% CI of the estimate was wide and did not exclude clinically important effects (see <a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Table S11</a></em>). A third PS-matched analysis was constructed to assess the association between treatment with MRAs and the risk of mortality in patients with a LVEF &gt;40%. This comprised of 1334 patients (667 treated with MRAs vs. 667 not treated with MRAs) and demonstrated that there was a 25% lower risk of mortality in patients treated with MRAs [HR 0.75 (95% CI 0.63–0.90), <em>P</em> = .002] (<em><a href="#ehad347-F3" class="usa-link">Figure 3</a></em> and <a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Table S12</a></em>). These findings were confirmed with sensitivity analysis, utilizing an ‘intention to treat’ approach [HR 0.78 (95% CI 0.65–0.94), <em>P</em> = .008]; and whereby patients were no longer censored for the start date of clinical trials and disease modifying therapy [HR 0.79 (95% CI 0.66–0.94), <em>P</em> = .009], and where MRA treatment was analysed as a time-varying exposure [HR 0.77 (95% CI 0.65–0.93), <em>P</em> = .005].</p>
<figure class="fig xbox font-sm" id="ehad347-F3"><h5 class="obj_head">Figure 3.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10424879_ehad347f3.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ede/10424879/f8afbfaec473/ehad347f3.jpg" loading="lazy" height="210" width="761" alt="Figure 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/ehad347-F3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Kaplan–Meier curves comparing survival in patients treated with MRAs to patients not treated with MRAs followed by a Cox proportional hazards regression analysis: (<em>A</em>) treatment with MRAs vs. no treatment with MRAs in the overall population, (<em>B</em>) treatment with MRAs vs. no treatment with MRAs in patients with a LVEF ≤40%, (<em>C</em>) treatment with MRAs vs. no treatment with MRAs in patients with a LVEF &gt;40%</p></figcaption></figure></section><section id="ehad347-s2.3.3"><h4 class="pmc_sec_title">Propensity score-matched analyses for combination therapy</h4>
<p>In the overall population, a PS-matched cohort was constructed to compare the association with risk of mortality, between treatment with all three classes of HF medications (beta-blockers, ACEi/ARBs, and MRAs) and treatment with two classes of HF medications (beta-blockers and ACEi/ARBs). This comprised of 680 patients (340 treated with all three HF medications vs. 340 treated with beta-blockers and ACEi/ARBs) and demonstrated that there was a 37% lower risk of mortality in patients treated with all three HF medications [HR 0.63 (95% CI 0.49–0.80), <em>P</em> &lt; .001] (see <a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Table S13</a></em>). These findings were confirmed with sensitivity analysis, utilizing an ‘intention to treat’ approach [HR 0.64 (95% CI 0.50–0.83), <em>P</em> &lt; .001]; and whereby patients were no longer censored for the start date of clinical trials and disease modifying therapy [HR 0.65 (95% CI 0.51–0.82), <em>P</em> &lt; .001], and where treatment was analysed as a time-varying exposure [HR 0.56 (95% CI 0.0.41–0.78), <em>P</em> = .001].</p>
<p>A PS-matched cohort was used to compare the association with risk of mortality, between treatment with two classes of HF medications (beta-blockers and ACEi/ARBs) and treatment with just ACEi/ARBs. This comprised of 558 patients (279 treated with beta-blockers and ACEi/ARBs vs. 279 treated with just ACEi/ARBs) and did not provide convincing evidence for a difference in the risk of mortality between the two groups [HR 1.06 (95% CI 0.81–1.39), <em>P</em> = .677], although the estimates were imprecise (see <a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Table S14</a></em> and <a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Figure S1</a></em>). Data on reasons for medication discontinuation and the association between survival and both medication dosage and medication discontinuation are presented in <a href="#sup1" class="usa-link">Supplementary data online</a>, <em><a href="#sup1" class="usa-link">Appendix S1</a></em>.</p></section></section></section><section id="ehad347-s3"><h2 class="pmc_sec_title">Discussion</h2>
<p>In this study we comprehensively evaluated the prescription pattern and discontinuation rates of HF medications in &gt;2000 patients with ATTR-CA, and assessed the association between treatment with HF medications and the risk of mortality in these individuals. Our study demonstrated that: (i) patients with ATTR-CA and a severe cardiac phenotype were more commonly treated with HF medications; (ii) beta-blockers and ACEi/ARBs were generally prescribed in low doses and often discontinued, whereas in contrast, MRAs were rarely discontinued; and (iii) MRAs were independently associated with a lower risk of mortality in the overall population, and in patients with LVEF &gt;40%; and low-dose beta-blockers were independently associated with a lower risk of mortality in patients with a LVEF ≤40% (<em><a href="#ehad347-ehad347_ga1" class="usa-link">Structured Graphical Abstract</a></em>).</p>
<p>In the overall population of patients with ATTR-CA, a relatively low proportion were treated with beta-blockers (55.4%), ACEi/ARBs (57.4%), and MRAs (39.0%). Treatment with HF medications in patients with ATTR-CA appears to be driven by the presence of comorbidities and the severity of their cardiac disease. Heart failure medications were more commonly prescribed in patients with atrial fibrillation, diabetes mellitus, and chronic kidney disease. Beta-blockers and ACEi/ARBs are also more commonly prescribed in patients with IHD.<sup><a href="#ehad347-B15" class="usa-link" aria-describedby="ehad347-B15">15</a>,<a href="#ehad347-B20" class="usa-link" aria-describedby="ehad347-B20">20</a></sup> Patients treated with conventional HF medications had more advanced cardiac disease as evidenced by worse functional capacity, a more severe NAC disease stage and lower indices of systolic function. Radial systolic impairment occurs in advanced ATTR-CA, and since the main evidence base for conventional HF medications is in patients with a LVEF ≤40%, the development of systolic impairment is likely to have contributed to greater use of HF medications in those with advanced cardiac disease.<sup><a href="#ehad347-B6" class="usa-link" aria-describedby="ehad347-B6">6–12</a></sup></p>
<p>Beta-blockers and ACEi/ARBs were commonly discontinued, with over one-fifth of patients having their beta-blocker discontinued, and nearly one-third having their ACEi/ARB discontinued during follow-up. Beta-blocker intolerance may be exacerbated the underlying pathophysiology of ATTR-CA. In the context of a fixed stroke volume, caused by restrictive physiology, a higher heart rate is required to maintain cardiac output. The inability to augment stroke volume in response to the vasodilation may also contribute to the intolerance of ACEi/ARBs.<sup><a href="#ehad347-B15" class="usa-link" aria-describedby="ehad347-B15">15</a>,<a href="#ehad347-B21" class="usa-link" aria-describedby="ehad347-B21">21</a></sup> In contrast, MRAs were rarely discontinued, with less than one-tenth having their MRA discontinued. This is probably related to the limited effect on blood pressure, compared with beta-blockers and ACEi/ARB, and their possible diuretic effect. The mainstay of symptom management in ATTR-CA has long been meticulous volume control, facilitated by high-dose loop diuretics. The MRAs may have a synergistic effect when utilized alongside loop diuretics and also increase potassium reabsorption, which is often needed when high doses of loop diuretics are utilized.<sup><a href="#ehad347-B22" class="usa-link" aria-describedby="ehad347-B22">22</a></sup></p>
<p>In the current study, which represents the largest analysis of HF medications in patients with ATTR-CA to date, both regression-based and PS-matched analyses demonstrated that treatment with MRAs was independently associated with a lower risk of mortality in the overall ATTR-CA population; and PS-matched analysis demonstrated that low-dose beta-blockers were associated with a lower risk of mortality in patients with a LVEF ≤40%. MRAs were associated with a lower risk of mortality in patients with a LVEF &gt;40%, but not in patients with a LVEF ≤40%. The point estimates for these analyses were similar, hence a greater sample size may have increased power sufficiently to demonstrate a benefit in patients with a LVEF ≤40%. Another possibility is that the benefit derived from MRAs is greater earlier in the disease process, and therefore increased survival benefit occurs in patients with a LVEF &gt;40%. The reduced risk of mortality associated with low-dose beta-blockers in patients with a LVEF ≤40% was maintained when excluding patients with concomitant IHD, suggesting that the benefit is related to treating ATTR-CA rather than treating comorbidities, and this is consistent with previous HF trials that demonstrated that improved outcomes were confined to patients with a reduced ejection fraction.<sup><a href="#ehad347-B6" class="usa-link" aria-describedby="ehad347-B6">6</a>,<a href="#ehad347-B7" class="usa-link" aria-describedby="ehad347-B7">7</a>,<a href="#ehad347-B12" class="usa-link" aria-describedby="ehad347-B12">12</a></sup></p>
<p>It has been well established that patients with ATTR-CA have a similar and possibly greater neurohormonal activation than is observed in patients with HF of different aetiologies. Furthermore, elevated neurohormone levels (specifically NT-proBNP and aldosterone) have been associated with a worse prognosis.<sup><a href="#ehad347-B23" class="usa-link" aria-describedby="ehad347-B23">23</a></sup> It is therefore plausible that patients with ATTR-CA would derive prognostic benefit from neurohormonal modulation. However, a recent position statement by the ESC on the treatment of ATTR-CA recommended the withdrawal of beta-blockers, avoiding ACEi/ARBs, and did not discuss the use of MRAs in patients with ATTR-CA, reflecting the perceived poor tolerability of these agents and lack of trial evidence to support their use (and lack of differentiation between AL and ATTR-CA, the former having greater intolerance).<sup><a href="#ehad347-B18" class="usa-link" aria-describedby="ehad347-B18">18</a></sup> Several small observational studies have contributed to these recommendations. However, differences in methodology and patient selection could explain our contrasting results. Previous studies have not matched patients, and therefore the worse outcomes in patients treated with HF medications were confounded by disease severity. Our study excluded patients with concomitant polyneuropathy, who often have autonomic disease and hypotension, resulting in a poor tolerance of HF medications.<sup><a href="#ehad347-B16" class="usa-link" aria-describedby="ehad347-B16">16</a>,<a href="#ehad347-B17" class="usa-link" aria-describedby="ehad347-B17">17</a></sup> Importantly, our results are supported by a retrospective analysis of the TOPCAT trial, whereby an enriched cohort with echocardiographic characteristics of CA derived benefit from MRA therapy.<sup><a href="#ehad347-B22" class="usa-link" aria-describedby="ehad347-B22">22</a></sup> This analysis is featured in a recent American College of Cardiology (ACC) consensus document that recommends MRA therapy alongside loop diuretics to augment diuresis.<sup><a href="#ehad347-B24" class="usa-link" aria-describedby="ehad347-B24">24</a></sup> Our study is the first to sub-categorize ATTR-CA patients by LVEF. The majority of HF patients with a LVEF ≤40% experience chronic adrenergic overstimulation, and higher serum noradrenaline levels than their counterparts with preserved systolic function. A similar pathophysiological mechanism may exist in ATTR-CA, and therefore patients with a LVEF ≤40% could derive benefit from beta-blockade.<sup><a href="#ehad347-B23" class="usa-link" aria-describedby="ehad347-B23">23</a></sup> Lastly, the majority were treated with bisoprolol (a cardio-selective beta-blocker), which potentially has a different haemodynamic profile to beta-blockers used in previous studies, while still providing neurohormonal modulation, and therefore, the observed benefit could potentially be confined to cardio-selective beta-blockers.</p>
<p>While the observational analyses reported here have limitations in their ability to provide causal estimates of treatments in individuals with ATTR-CA, they do raise the question as to whether there could be benefit from some neurohumoral therapies in such patients and support testing this hypothesis in prospective randomized controlled trials.<sup><a href="#ehad347-B22" class="usa-link" aria-describedby="ehad347-B22">22</a></sup> While clinical trials are clearly needed, we believe that the data presented in this study call into question the consensus recommendations to discontinue beta-blockers and that neglect to mention MRAs.<sup><a href="#ehad347-B18" class="usa-link" aria-describedby="ehad347-B18">18</a></sup></p></section><section id="ehad347-s4"><h2 class="pmc_sec_title">Limitations</h2>
<p>There is an unavoidable prescription bias, with comorbid patients with more advanced cardiac disease being treated with more HF medications; but it is also possible that clinicians may have avoided using HF medications in some higher risk patients. Treatment decisions were made on a case-by-case basis, and therefore clinical decisions must factor in each individual’s tolerance of HF medications. It is possible that patients may have discontinued HF medications prior to their first NAC assessment, and this could not be factored into the analysis. Although we performed multivariable adjustment and PS matching to account for confounders known to impact mortality in ATTR-CA, we cannot exclude the possibility of residual confounding. The present study should be considered hypothesis-generating and highlights the urgent need for randomized controlled trials. Some of the estimated HRs generated following pre-specified subgroup analysis were imprecise, and is likely to reflect the unavoidably small sample size. Lastly, a small minority were treated with angiotensin receptor-neprilysin inhibitors or sodium-glucose cotransporter 2 inhibitors and had a short duration of follow-up. Therefore, they were not included in the present study, and further studies will be required to assess these medications in patients with ATTR-CA.</p></section><section id="ehad347-s5"><h2 class="pmc_sec_title">Conclusions</h2>
<p>In summary, in this large cohort of patients with ATTR-CA, a relatively low proportion were treated with conventional HF medications, and those that had a more severe cardiac phenotype were more commonly treated with HF medications. Beta-blockers and ACEi/ARBs were often prescribed at a low dose, and frequently discontinued; in contrast to MRAs which were rarely discontinued. Both regression and PS-matched analyses demonstrated that treatment with a MRA was independently associated with a lower risk of mortality in the overall ATTR-CA population; and PS-matched analysis demonstrated that treatment with a low-dose beta-blocker was independently associated with a lower risk of mortality in patients with a LVEF ≤40%, but these findings require confirmation in prospective randomized controlled trials.</p></section><section id="ehad347-s6"><h2 class="pmc_sec_title">Supplementary data</h2>
<p>
<a href="#sup1" class="usa-link">Supplementary data</a> are available at <em>European Heart Journal</em> online.</p></section><section id="ehad347-s7"><h2 class="pmc_sec_title">Declarations</h2>
<section id="ehad347-s7.4"><h3 class="pmc_sec_title">Disclosure of Interest</h3>
<p>All authors declare no conflict of interest for this contribution.</p></section></section><section id="sec27"><h2 class="pmc_sec_title">Supplementary Material</h2>
<section class="sm xbox font-sm" id="sup1"><div class="caption p"><span>ehad347_Supplementary_Data</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/10424879/bin/ehad347_supplementary_data.docx" data-ga-action="click_feat_suppl" class="usa-link">ehad347_supplementary_data.docx</a><sup> (4MB, docx) </sup>
</div></div></section></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Adam Ioannou, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Paolo Massa, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Rishi K Patel, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Yousuf Razvi, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Aldostefano Porcari, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK; 
Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Via Giacomo Puccini, Trieste 34100, Italy.</p>
<p>Muhammad U Rauf, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Anita Jiang, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Giacomo Cabras, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Stefano Filisetti, 
Cardiology University Department, IRCCS Policlinico San Donato, Piazza Edmondo Malan, Milan 20097, Italy.</p>
<p>Roos E Bolhuis, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Francesco Bandera, 
Cardiology University Department, IRCCS Policlinico San Donato, Piazza Edmondo Malan, Milan 20097, Italy.</p>
<p>Lucia Venneri, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Ana Martinez-Naharro, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Steven Law, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Tushar Kotecha, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Ruta Virsinskaite, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Daniel S Knight, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Michele Emdin, 
Health Science Interdisciplinary Center, Scuola Superiore Sant’Anna, Via Giuseppe Moruzzi, Pisa 56127, Italy; 
Cardiovascular Department, Fondazione Toscana Gabriele Monasterio, Via Giuseppe Moruzzi, Pisa 56124, Italy.</p>
<p>Aviva Petrie, 
Biostatistics Unit, University College London Eastman Dental Institute, 256 Grays Inn Road, London WC1X 8LD, UK.</p>
<p>Helen Lachmann, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Ashutosh Wechelakar, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Mark Petrie, 
BHF Cardiovascular Research Centre, University of Glasgow, 126 University Pl, Glasgow G12 8TA, UK.</p>
<p>Alun Hughes, 
Institute of Cardiovascular Science, University College London, 1–19 Torrington Place, London WC1E 7HB, UK.</p>
<p>Nick Freemantle, 
University College London, London, UK.</p>
<p>Philip N Hawkins, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Carol Whelan, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>John J V McMurray, 
BHF Cardiovascular Research Centre, University of Glasgow, 126 University Pl, Glasgow G12 8TA, UK.</p>
<p>Julian D Gillmore, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p>
<p>Marianna Fontana, 
National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.</p></section><section id="ehad347-s7.3"><h2 class="pmc_sec_title">Data Availability</h2>
<p>The data underlying this article cannot be shared due to restrictions from the institutional ethics committee to protect patient privacy.</p></section><section id="ehad347-s7.5"><h2 class="pmc_sec_title">Funding</h2>
<p>All authors declare no funding for this contribution.</p></section><section id="ehad347-s7.2"><h2 class="pmc_sec_title">Ethical Approval</h2>
<p>Ethical Approval was not required.</p></section><section id="ehad347-7.16"><h2 class="pmc_sec_title">Pre-registered Clinical Trial Number</h2>
<p>None supplied.</p></section><section id="ref1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="ehad347-B1">
<span class="label">1.</span><cite>
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:2872–2891. 10.1016/j.jacc.2019.04.003
</cite> [<a href="https://doi.org/10.1016/j.jacc.2019.04.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6724183/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31171094/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Transthyretin%20amyloid%20cardiomyopathy:%20JACC%20state-of-the-art%20review&amp;volume=73&amp;publication_year=2019&amp;pages=2872-2891&amp;pmid=31171094&amp;doi=10.1016/j.jacc.2019.04.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B2">
<span class="label">2.</span><cite>
Ioannou A, Patel RK, Razvi Y, Porcari A, Knight D, Martinez-Naharro A, et al. 
Multi-imaging characterization of cardiac phenotype in different types of amyloidosis. JACC Cardiovasc Imaging 2022;16:464–477. 10.1016/j.jcmg.2022.07.008
</cite> [<a href="https://doi.org/10.1016/j.jcmg.2022.07.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36648052/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JACC%20Cardiovasc%20Imaging&amp;title=Multi-imaging%20characterization%20of%20cardiac%20phenotype%20in%20different%20types%20of%20amyloidosis&amp;volume=16&amp;publication_year=2022&amp;pages=464-477&amp;pmid=36648052&amp;doi=10.1016/j.jcmg.2022.07.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B3">
<span class="label">3.</span><cite>
Ioannou A, Patel RK, Razvi Y, Porcari A, Sinagra G, Venneri L, et al. 
Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation 2022;146:1657–1670. 10.1161/CIRCULATIONAHA.122.060852
</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.122.060852" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9698091/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36325894/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Impact%20of%20earlier%20diagnosis%20in%20cardiac%20ATTR%20amyloidosis%20over%20the%20course%20of%2020%20years&amp;volume=146&amp;publication_year=2022&amp;pages=1657-1670&amp;pmid=36325894&amp;doi=10.1161/CIRCULATIONAHA.122.060852&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B4">
<span class="label">4.</span><cite>
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. 
Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007–1016. 10.1056/NEJMoa1805689
</cite> [<a href="https://doi.org/10.1056/NEJMoa1805689" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30145929/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Tafamidis%20treatment%20for%20patients%20with%20transthyretin%20amyloid%20cardiomyopathy&amp;volume=379&amp;publication_year=2018&amp;pages=1007-1016&amp;pmid=30145929&amp;doi=10.1056/NEJMoa1805689&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B5">
<span class="label">5.</span><cite>
Kazi DS, Bellows BK, Baron SJ, Shen C, Cohen DJ, Spertus JA, et al. 
Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation 2020;141:1214–1224. 10.1161/CIRCULATIONAHA.119.045093
</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.119.045093" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7156331/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32078382/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Cost-effectiveness%20of%20tafamidis%20therapy%20for%20transthyretin%20amyloid%20cardiomyopathy&amp;volume=141&amp;publication_year=2020&amp;pages=1214-1224&amp;pmid=32078382&amp;doi=10.1161/CIRCULATIONAHA.119.045093&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B6">
<span class="label">6.</span><cite>
Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. 
Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001–2007. 10.1016/S0140-6736(99)04440-210376614
</cite> [<a href="https://doi.org/10.1016/S0140-6736(99)04440-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Effect%20of%20metoprolol%20CR/XL%20in%20chronic%20heart%20failure:%20metoprolol%20CR/XL%20randomised%20intervention%20trial%20in%20congestive%20heart%20failure%20(MERIT-HF)&amp;volume=353&amp;publication_year=1999&amp;pages=2001-2007&amp;doi=10.1016/S0140-6736(99)04440-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B7">
<span class="label">7.</span><cite>
Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. 
Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–1658. 10.1056/NEJM200105313442201
</cite> [<a href="https://doi.org/10.1056/NEJM200105313442201" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11386263/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Effect%20of%20carvedilol%20on%20survival%20in%20severe%20chronic%20heart%20failure&amp;volume=344&amp;publication_year=2001&amp;pages=1651-1658&amp;pmid=11386263&amp;doi=10.1056/NEJM200105313442201&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B8">
<span class="label">8.</span><cite>
SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293–302. 10.1056/NEJM199108013250501
</cite> [<a href="https://doi.org/10.1056/NEJM199108013250501" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2057034/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Effect%20of%20enalapril%20on%20survival%20in%20patients%20with%20reduced%20left%20ventricular%20ejection%20fractions%20and%20congestive%20heart%20failure&amp;volume=325&amp;publication_year=1991&amp;pages=293-302&amp;pmid=2057034&amp;doi=10.1056/NEJM199108013250501&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B9">
<span class="label">9.</span><cite>
Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJV, et al. 
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004;110:2180–2183. 10.1161/01.CIR.0000144474.65922.AA
</cite> [<a href="https://doi.org/10.1161/01.CIR.0000144474.65922.AA" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15466644/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Effect%20of%20candesartan%20on%20cause-specific%20mortality%20in%20heart%20failure%20patients:%20the%20Candesartan%20in%20Heart%20failure%20Assessment%20of%20Reduction%20in%20Mortality%20and%20morbidity%20(CHARM)%20program&amp;volume=110&amp;publication_year=2004&amp;pages=2180-2183&amp;pmid=15466644&amp;doi=10.1161/01.CIR.0000144474.65922.AA&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B10">
<span class="label">10.</span><cite>
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. 
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709–717. 10.1056/NEJM199909023411001
</cite> [<a href="https://doi.org/10.1056/NEJM199909023411001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10471456/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=The%20effect%20of%20spironolactone%20on%20morbidity%20and%20mortality%20in%20patients%20with%20severe%20heart%20failure.%20Randomized%20aldactone%20evaluation%20study%20investigators&amp;volume=341&amp;publication_year=1999&amp;pages=709-717&amp;pmid=10471456&amp;doi=10.1056/NEJM199909023411001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B11">
<span class="label">11.</span><cite>
Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. 
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21. 10.1056/NEJMoa1009492
</cite> [<a href="https://doi.org/10.1056/NEJMoa1009492" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21073363/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Eplerenone%20in%20patients%20with%20systolic%20heart%20failure%20and%20mild%20symptoms&amp;volume=364&amp;publication_year=2011&amp;pages=11-21&amp;pmid=21073363&amp;doi=10.1056/NEJMoa1009492&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B12">
<span class="label">12.</span><cite>
Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, et al. 
Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26–35. 10.1093/eurheartj/ehx564
</cite> [<a href="https://doi.org/10.1093/eurheartj/ehx564" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5837435/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29040525/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Beta-blockers%20for%20heart%20failure%20with%20reduced,%20mid-range,%20and%20preserved%20ejection%20fraction:%20an%20individual%20patient-level%20analysis%20of%20double-blind%20randomized%20trials&amp;volume=39&amp;publication_year=2018&amp;pages=26-35&amp;pmid=29040525&amp;doi=10.1093/eurheartj/ehx564&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B13">
<span class="label">13.</span><cite>
Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, et al. 
Declining risk of sudden death in heart failure. N Engl J Med 2017;377:41–51. 10.1056/NEJMoa1609758
</cite> [<a href="https://doi.org/10.1056/NEJMoa1609758" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28679089/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Declining%20risk%20of%20sudden%20death%20in%20heart%20failure&amp;volume=377&amp;publication_year=2017&amp;pages=41-51&amp;pmid=28679089&amp;doi=10.1056/NEJMoa1609758&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B14">
<span class="label">14.</span><cite>
Aimo A, Vergaro G, Castiglione V, Rapezzi C, Emdin M. Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis. Eur J Intern Med 2020;80:66–72. 10.1016/j.ejim.2020.05.015
</cite> [<a href="https://doi.org/10.1016/j.ejim.2020.05.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32475765/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Intern%20Med&amp;title=Safety%20and%20tolerability%20of%20neurohormonal%20antagonism%20in%20cardiac%20amyloidosis&amp;volume=80&amp;publication_year=2020&amp;pages=66-72&amp;pmid=32475765&amp;doi=10.1016/j.ejim.2020.05.015&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B15">
<span class="label">15.</span><cite>
Tini G, Cappelli F, Biagini E, Musumeci B, Merlo M, Crotti L, et al. 
Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey. ESC Heart Fail 2021;8:3369–3374. 10.1002/ehf2.13411
</cite> [<a href="https://doi.org/10.1002/ehf2.13411" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8318433/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33988312/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ESC%20Heart%20Fail&amp;title=Current%20patterns%20of%20beta-blocker%20prescription%20in%20cardiac%20amyloidosis:%20an%20Italian%20nationwide%20survey&amp;volume=8&amp;publication_year=2021&amp;pages=3369-3374&amp;pmid=33988312&amp;doi=10.1002/ehf2.13411&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B16">
<span class="label">16.</span><cite>
Aus dem Siepen F, Hein S, Bauer R, Katus HA, Kristen AV. Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful? Amyloid 2017;24:132–133. 10.1080/13506129.2016.1272453
</cite> [<a href="https://doi.org/10.1080/13506129.2016.1272453" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28434295/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Standard%20heart%20failure%20medication%20in%20cardiac%20transthyretin%20amyloidosis:%20useful%20or%20harmful?&amp;volume=24&amp;publication_year=2017&amp;pages=132-133&amp;pmid=28434295&amp;doi=10.1080/13506129.2016.1272453&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B17">
<span class="label">17.</span><cite>
Cheng RK, Vasbinder A, Levy WC, Goyal P, Griffin JM, Leedy DJ, et al. 
Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis. J Am Heart Assoc 2021;10:e022859. 10.1161/JAHA.121.022859</cite> [<a href="https://doi.org/10.1161/JAHA.121.022859" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9075255/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34729989/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Heart%20Assoc&amp;title=Lack%20of%20association%20between%20neurohormonal%20blockade%20and%20survival%20in%20transthyretin%20cardiac%20amyloidosis&amp;volume=10&amp;publication_year=2021&amp;pmid=34729989&amp;doi=10.1161/JAHA.121.022859&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B18">
<span class="label">18.</span><cite>
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. 
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology working group on myocardial and pericardial diseases. Eur J Heart Fail 2021;23:512–526. 10.1002/ejhf.2140
</cite> [<a href="https://doi.org/10.1002/ejhf.2140" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33826207/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=Diagnosis%20and%20treatment%20of%20cardiac%20amyloidosis.%20A%20position%20statement%20of%20the%20European%20Society%20of%20Cardiology%20working%20group%20on%20myocardial%20and%20pericardial%20diseases&amp;volume=23&amp;publication_year=2021&amp;pages=512-526&amp;pmid=33826207&amp;doi=10.1002/ejhf.2140&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B19">
<span class="label">19.</span><cite>
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599–3726.34447992
</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=2021%20ESC%20guidelines%20for%20the%20diagnosis%20and%20treatment%20of%20acute%20and%20chronic%20heart%20failure:%20developed%20by%20the%20task%20force%20for%20the%20diagnosis%20and%20treatment%20of%20acute%20and%20chronic%20heart%20failure%20of%20the%20European%20Society%20of%20Cardiology%20(ESC)%20with%20the%20special%20contribution%20of%20the%20Heart%20Failure%20Association%20(HFA)%20of%20the%20ESC&amp;volume=42&amp;publication_year=2021&amp;pages=3599-3726&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B20">
<span class="label">20.</span><cite>
Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. 
Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 2018;72:351–366. 10.1016/j.jacc.2018.04.070
</cite> [<a href="https://doi.org/10.1016/j.jacc.2018.04.070" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30025570/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Medical%20therapy%20for%20heart%20failure%20with%20reduced%20ejection%20fraction:%20the%20CHAMP-HF%20registry&amp;volume=72&amp;publication_year=2018&amp;pages=351-366&amp;pmid=30025570&amp;doi=10.1016/j.jacc.2018.04.070&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B21">
<span class="label">21.</span><cite>
Barge-Caballero G, Barge-Caballero E, López-Pérez M, Bilbao-Quesada R, González-Babarro E, Gómez-Otero Iet al. 
Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy. Mayo Clin Proc 2022;97:261–273. 10.1016/j.mayocp.2021.08.006
</cite> [<a href="https://doi.org/10.1016/j.mayocp.2021.08.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34802727/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mayo%20Clin%20Proc&amp;title=Beta-blocker%20exposure%20and%20survival%20in%20patients%20with%20transthyretin%20amyloid%20cardiomyopathy&amp;volume=97&amp;publication_year=2022&amp;pages=261-273&amp;pmid=34802727&amp;doi=10.1016/j.mayocp.2021.08.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B22">
<span class="label">22.</span><cite>
Sperry BW, Hanna M, Shah SJ, Jaber WA, Spertus JA. Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: results from TOPCAT. JACC Heart Fail 2021;9:795–802. 10.1016/j.jchf.2021.06.007
</cite> [<a href="https://doi.org/10.1016/j.jchf.2021.06.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34509404/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JACC%20Heart%20Fail&amp;title=Spironolactone%20in%20patients%20with%20an%20echocardiographic%20HFpEF%20phenotype%20suggestive%20of%20cardiac%20amyloidosis:%20results%20from%20TOPCAT&amp;volume=9&amp;publication_year=2021&amp;pages=795-802&amp;pmid=34509404&amp;doi=10.1016/j.jchf.2021.06.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B23">
<span class="label">23.</span><cite>
Vergaro G, Aimo A, Campora A, Castiglione V, Prontera C, Masotti S, et al. 
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure. Amyloid 2021;28:252–258. 10.1080/13506129.2021.1966624
</cite> [<a href="https://doi.org/10.1080/13506129.2021.1966624" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34396857/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Patients%20with%20cardiac%20amyloidosis%20have%20a%20greater%20neurohormonal%20activation%20than%20those%20with%20non-amyloidotic%20heart%20failure&amp;volume=28&amp;publication_year=2021&amp;pages=252-258&amp;pmid=34396857&amp;doi=10.1080/13506129.2021.1966624&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehad347-B24">
<span class="label">24.</span><cite>
Writing Committee; Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, et al. 
2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol 2023;81:1076–1126. 10.1016/j.jacc.2022.11.022
</cite> [<a href="https://doi.org/10.1016/j.jacc.2022.11.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36697326/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=2023%20ACC%20expert%20consensus%20decision%20pathway%20on%20comprehensive%20multidisciplinary%20care%20for%20the%20patient%20with%20cardiac%20amyloidosis:%20a%20report%20of%20the%20American%20College%20of%20Cardiology%20solution%20set%20oversight%20committee&amp;volume=81&amp;publication_year=2023&amp;pages=1076-1126&amp;pmid=36697326&amp;doi=10.1016/j.jacc.2022.11.022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>ehad347_Supplementary_Data</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/10424879/bin/ehad347_supplementary_data.docx" data-ga-action="click_feat_suppl" class="usa-link">ehad347_supplementary_data.docx</a><sup> (4MB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data underlying this article cannot be shared due to restrictions from the institutional ethics committee to protect patient privacy.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from European Heart Journal are provided here courtesy of <strong>Oxford University Press</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1093/eurheartj/ehad347"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/ehad347.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (825.3 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/10424879/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/10424879/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC10424879%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC10424879/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC10424879/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC10424879/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/37216684/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC10424879/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/37216684/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC10424879/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/10424879/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="9o07iepRePSYzE5glQxM2sqYWowa7sfva7NOLZN3bb7uT7oBz4CsQ6SyHcMKK2W9">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
